AB 1645: Health care coverage: cost sharing.
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2023-09-18
Current Status:
Failed
(2024-01-29: Consideration of Governor's veto stricken from file.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a group or individual nongrandfathered health care service plan contract or health insurance policy to provide coverage for, and prohibits a contract or policy from imposing cost-sharing requirements for, specified preventive care services and screenings.
This bill would prohibit a group or individual health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement for office visits for the above-described preventive care services and screenings and for items or services that are integral to their provision. The bill would prohibit large group contracts and policies issued, amended, or renewed on or after January 1, 2024, and an individual or small group health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025, from imposing a cost-sharing requirement, utilization review, or other specified limits on a recommended sexually transmitted infections screening, and from imposing a cost-sharing requirement for any items and services integral to a sexually transmitted infections screening, as specified. The bill would require a plan or insurer to directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening that meets specified criteria for screening tests and integral items and services rendered, as specified, and would prohibit a nonparticipating provider from billing or collecting a cost-sharing amount for a sexually transmitted infections screening from an enrollee or insured. Because a violation of the bills requirements by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a group or individual nongrandfathered health care service plan contract or health insurance policy to provide coverage for, and prohibits a contract or policy from imposing cost-sharing requirements for, specified preventive care services and screenings.
This bill would prohibit a group or individual health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement for office visits for the above-described preventive care services and screenings and for items or services that are integral to their provision. The bill would prohibit large group contracts and policies issued, amended, or renewed on or after January 1, 2024, and an individual or small group health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025, from imposing a cost-sharing requirement, utilization review, or other specified limits on a recommended sexually transmitted infections screening, and from imposing a cost-sharing requirement for any items and services integral to a sexually transmitted infections screening, as specified. The bill would require a plan or insurer to directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening that meets specified criteria for screening tests and integral items and services rendered, as specified, and would prohibit a nonparticipating provider from billing or collecting a cost-sharing amount for a sexually transmitted infections screening from an enrollee or insured. Because a violation of the bills requirements by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a group or individual nongrandfathered health care service plan contract or health insurance policy to provide coverage for, and prohibits a contract or policy from imposing cost-sharing requirements for, specified preventive care services and screenings.
This bill would prohibit a group or individual health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement for office visits for the above-described preventive care services and screenings and for items or services that are integral to their provision. The bill would prohibit contracts and policies from imposing a cost-sharing requirement, utilization review, or other specified limits on a recommended sexually transmitted infections screening, and from imposing a cost-sharing requirement for any items and services integral to a sexually transmitted infections screening, as specified. The bill would require a plan or insurer to directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening that meets specified criteria for screening tests and integral items and services rendered, as specified, and would prohibit a nonparticipating provider from billing or collecting a cost-sharing amount for a sexually transmitted infections screening from an enrollee or insured. Because a violation of the bills requirements by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a group or individual nongrandfathered health care service plan contract or health insurance policy to provide coverage for, and prohibits a contract or policy from imposing cost-sharing requirements for, specified preventive care services and screenings.
This bill would prohibit a group or individual nongrandfathered health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement for office visits for the above-described preventive care services and screenings and for items or services that are integral to their provision. The bill would prohibit nongrandfathered and grandfathered contracts and policies from imposing a cost-sharing requirement, utilization review, or other specified limits on a recommended sexually transmitted infections screening, and from imposing a cost-sharing requirement for any items and services integral to a sexually transmitted infections screening, as specified. The bill would require a plan or insurer to directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening that meets specified criteria its median contracted rate in the general geographic region for screening tests and integral items and services rendered, as specified, and would prohibit a nonparticipating provider from billing or collecting a cost-sharing amount for a sexually transmitted infections screening from an enrollee or insured. Because a violation of the bills requirements by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a group or individual nongrandfathered health care service plan contract or health insurance policy to provide coverage for, and prohibits a contract or policy from imposing cost-sharing requirements for, specified preventive care services and screenings.
This bill would prohibit a group or individual nongrandfathered health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement for office visits for the above-described preventive care services and screenings and for items or services that are integral to their provision. The bill would prohibit those nongrandfathered and grandfathered contracts and policies from imposing a cost-sharing requirement, utilization review, or other specified limits on a recommended sexually transmitted infections screening, and from imposing a cost-sharing requirement for any items and services integral to a sexually transmitted infections screening, as specified. The bill would require a plan or insurer to directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening that meets specified criteria its median contracted rate in the general geographic region for screening tests and integral items and services rendered, and would prohibit a nonparticipating provider from billing or collecting a cost-sharing amount for a sexually transmitted infections screening from an enrollee or insured. Because a violation of the bills requirements by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a group or individual nongrandfathered health care service plan contract or health insurance policy to provide coverage for, and prohibits a contract or policy from imposing cost-sharing requirements for, specified preventive care services and screenings.
This bill would prohibit a group or individual nongrandfathered health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement for office visits for the above-described preventive care services and screenings and for items or services that are integral to their provision. The bill would prohibit those contracts and policies from imposing a cost-sharing requirement, utilization review, or other specified limits on a recommended sexually transmitted infections screening, and from imposing a cost-sharing requirement for any items and services integral to a sexually transmitted infections screening, as specified. The bill would require a plan or insurer to directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening that meets specified criteria its median contracted rate in the general geographic region for screening tests and integral items and services rendered, and would prohibit a nonparticipating provider from billing or collecting a cost-sharing amount for a sexually transmitted infections screening from an enrollee or insured. Because a violation of the bills requirements by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(a)A group or individual health care service plan contract shall, at a minimum, provide coverage for, and shall not impose any cost-sharing requirements for, any of the following:
(1)Evidence-based items or services that have in effect a rating of A or B in the recommendations of the United States Preventive Services Task Force, as periodically updated.
(2)Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention with respect to the individual involved.
(3)With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the United States Health Resources and Services Administration.
(4)With respect to women, those additional preventive care and screenings not described in paragraph (1) as provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration for purposes of this paragraph.
(5)For the purposes of this section:
(A)The current recommendations of the United States Preventive Services Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current, not including those issued in or around November 2009.
(B)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by this subdivision, or for any items or services that are integral to the provision of an item or service that is required by this subdivision, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by this subdivision.
(i)Integral item or service means an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this subdivision.
(ii)Current, generally accepted standard of care or clinical practice means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention, and product labeling approved by the United States Food and Drug Administration.
(b)This section does not prohibit a health care service plan from doing either of the following:
(1)Providing coverage for preventive items or services in addition to those required by subdivision (a).
(2)Denying coverage for services that are not recommended by the United States Preventive Services Task Force, except as provided by subdivision (d).
(c)A health care service plan shall provide coverage pursuant to subdivision (a) for plan years that begin on or after the date that is one year after the date that a novel recommendation or guideline is issued. A health care service plan shall provide coverage for modified or upgraded recommendations or guidelines pursuant to subdivision (a) no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
(1)A health care service plan that is required to provide coverage for any items and services specified in a recommendation or guideline described in subdivision (a) on the first day of a plan year shall provide coverage through the last day of the plan year, even if the recommendation or guideline changes or is no longer described in subdivision (a) during the plan year.
(2)Notwithstanding paragraph (1), if a recommendation or guideline described in paragraph (1) of subdivision (a) that was in effect on the first day of a plan year is downgraded to a D rating, or if any item or service associated with any recommendation or guideline specified in subdivision (a) is subject to a safety recall or is otherwise determined to pose a significant safety concern by a federal agency authorized to regulate the item or service during a plan year, a health care service plan is not required to cover the item or service through the last day of the plan year.
(d)(1)A health care service plan contract shall cover items and services pursuant to this section in accordance with any applicable requirement of this chapter, including, but not limited to, Sections 1342.74 on prophylaxis of HIV infection, 1367.0021 on sexually transmitted infections screening, 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021 on home test kits for sexually transmitted diseases, and 1367.668 on colorectal cancer screening.
(2)Notwithstanding paragraph (1), Section 1367.25 shall exclusively govern the coverage of contraceptive drugs, devices, and products pursuant to this chapter.
(e)This section does not apply to a health care service plan contract that is a grandfathered health plan, or to a specialized health care service plan that does not cover an essential health benefit, as defined in Section 1367.005. The cost-sharing requirements of this section shall only apply to a health savings account-eligible health care service plan to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(f)The department shall coordinate with the Department of Insurance if it adopts regulations to implement this section.
SEC. 2.Section 1367.0021 is added to the Health and Safety Code, to read:1367.0021.(a)In addition to the items and services that are required by Section 1367.002, a large group health care service plan contract issued, amended, or renewed on or after January 1, 2024, or an individual or small group contract issued, amended, or renewed on or after January 1, 2025, shall not impose a cost-sharing requirement on a sexually transmitted infections screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) in the most recently updated version of its Sexually Transmitted Infections Treatment Guidelines or as most recently recommended by the CDC in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the United States Preventive Services Task Force conflicts with that of the CDC, or omits a CDC screening recommendation, a health care service plan contract shall not require any cost sharing for a sexually transmitted infections screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDCs recommendation.
(b)Notwithstanding Section 2713 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-13), a health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not require or impose any of the following for coverage of sexually transmitted infections screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
(1)Prior authorization or other utilization review requirements.
(2)Limits on frequency, method, treatment, or setting.
(3)Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
(4)Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
(5)Any other limits on the coverage or provision of sexually transmitted infections screening as a preventive item or service under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice, as prohibited by this chapter.
(c)A large group health care service plan contract issued, amended, or renewed on or after January 1, 2024, or an individual or small group contract issued, amended, or renewed on or after January 1, 2025, shall not impose a cost-sharing requirement for sexually transmitted infections screening, or for any items and services that are integral to a screening, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, regardless of any of the following:
(1)The location of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting.
(2)The screening test, testing method or algorithm, or method of sample collection or processing.
(3)The identity or qualifications of the individual who collected or processed a sample.
(4)The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
(d)(1)A health care service plan shall directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. If a nonparticipating essential community provider does not generate the results of screening, the provider shall submit the samples to a participating processing laboratory. A nonparticipating essential community provider shall not bill or collect any cost-sharing amounts from an enrollee for a sexually transmitted infections screening, or for integral items and services, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021.
(2)For items and services rendered subject to this section, unless otherwise agreed to by a nonparticipating essential community provider and the health care service plan, the plan shall reimburse an essential community provider the greater of its average contracted rate or 125 percent of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered.
(e)For purposes of this section:
(1)Average contracted rate means the average of the contracted commercial rates paid by the health care service plan for the same or similar items or services in the geographic region.
(2)Essential community provider means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchanges Essential Community Provider List.
(3)General geographic region has the same meaning as provided by Section 1371.31 and the regulations promulgated thereunder.
(4)Gender means sex, including gender identity and gender expression.
(5)Gender expression means gender-related appearance and behavior, whether or not stereotypically associated with assigned sex at birth.
(6)Utilization review has the same meaning as defined by Section 1374.721 and any regulations promulgated thereunder.
(f)This section does not apply to a specialized health care service plan contract that does not cover an essential health benefit, as defined by Section 1367.005. If a health care service plan contract is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible on sexually transmitted infections screening, or on integral items and services, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, unless not applying the deductible would conflict with federal requirements for high deductible health plans.
(g)The delayed implementation of subdivisions (a) and (c) for individual and small group health care service plan contracts does not excuse compliance with Section 1367.002. An individual or small group health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall comply with the coverage and cost-sharing requirements for sexually transmitted infections screening under Section 1367.002.
SEC. 3.Section 10112.2 of the Insurance Code is amended to read:10112.2.(a)A group or individual health insurance policy shall, at a minimum, provide coverage for, and shall not impose any cost-sharing requirements for, any of the following:
(1)Evidence-based items or services that have in effect a rating of A or B in the recommendations of the United States Preventive Services Task Force, as periodically updated.
(2)Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention with respect to the individual involved.
(3)With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the United States Health Resources and Services Administration.
(4)With respect to women, those additional preventive care and screenings not described in paragraph (1) as provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration for purposes of this paragraph.
(5)For the purposes of this section:
(A)The current recommendations of the United States Preventive Services Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current, not including those issued in or around November 2009.
(B)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by this subdivision, or for any items or services that are integral to the provision of an item or service that is required by this subdivision, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by this subdivision.
(i)Integral item or service means an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this subdivision.
(ii)Current, generally accepted standard of care or clinical practice means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention, and product labeling approved by the United States Food and Drug Administration.
(b)This section does not prohibit a health insurer from doing either of the following:
(1)Providing coverage for services in addition to those required by subdivision (a).
(2)Denying coverage for services that are not recommended by the United States Preventive Services Task Force, except as provided by subdivision (d).
(c)A health insurer shall provide coverage pursuant to subdivision (a) for policy years that begin on or after the date that is one year after the date that a novel recommendation or guideline is issued. A health insurer shall provide coverage for modified or upgraded recommendations or guidelines pursuant to subdivision (a) no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
(1)A health insurer that is required to provide coverage for any items and services specified in a recommendation or guideline described in subdivision (a) on the first day of a policy year shall provide coverage through the last day of the policy year, even if the recommendation or guideline changes or is no longer described in subdivision (a) during the policy year.
(2)Notwithstanding paragraph (1), if a recommendation or guideline described in paragraph (1) of subdivision (a) that was in effect on the first day of a policy year is downgraded to a D rating, or if any item or service associated with any recommendation or guideline specified in subdivision (a) is subject to a safety recall or is otherwise determined to pose a significant safety concern by a federal agency authorized to regulate the item or service during a policy year, a health insurer is not required to cover the item or service through the last day of the policy year.
(d)(1)A health insurance policy shall cover items and services pursuant to this section in accordance with any applicable requirement of this part, including, but not limited to, Sections 10112.20 on sexually transmitted infections screening, 10123.1933 on prophylaxis of HIV infection, 10123.207 on colorectal cancer screening, and 10123.208 on home test kits for sexually transmitted diseases.
(2)Notwithstanding paragraph (1), Section 10123.196 shall exclusively govern the coverage of contraceptive drugs, devices, and products pursuant to this part.
(e)This section does not apply to a health insurance policy that is a grandfathered health plan, or to a specialized health insurance policy that does not cover an essential health benefit, as defined in Section 10112.27. The cost-sharing requirements of this section shall only apply to a health savings account-eligible health insurance policy to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(f)The department shall coordinate with the Department of Managed Health Care if it adopts regulations to implement this section.
(g)The commissioner and department may exercise the authority provided by this code and the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340), Chapter 4.5 (commencing with Section 11400), and Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code) to implement and enforce this section and all related sections, including those referenced herein. If the commissioner assesses a civil penalty for a violation, any hearing that is requested by the insurer shall be conducted by an administrative law judge of the Administrative Hearing Bureau of the department under the formal procedure of Chapter 5. This subdivision does not impair or restrict the commissioners authority pursuant to another provision of this code or the Administrative Procedure Act.
SEC. 4.Section 10112.20 is added to the Insurance Code, immediately following Section 10112.2, to read:10112.20.(a)In addition to the items and services that are required by Section 10112.2, a large group health insurance policy or policy subject to Section 10965.03 issued, amended, or renewed on or after January 1, 2024, or an individual or small group policy issued, amended, or renewed on or after January 1, 2025, shall not impose a cost-sharing requirement on a sexually transmitted infections screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) in the most recently updated version of its Sexually Transmitted Infections Treatment Guidelines or as most recently recommended by the CDC in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the United States Preventive Services Task Force conflicts with that of the CDC, or omits a CDC screening recommendation, a health insurance policy shall not require any cost sharing for a sexually transmitted infections screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDCs recommendation.
(b)Notwithstanding Section 2713 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-13), a health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not require or impose any of the following for coverage of sexually transmitted infections screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
(1)Prior authorization or other utilization review requirements.
(2)Limits on frequency, method, treatment, or setting.
(3)Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
(4)Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
(5)Any other limits on the coverage or provision of sexually transmitted infections screening as a preventive item or service under this section, Section 10112.2, or Section 10123.208, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this chapter.
(c)A large group health insurance policy or policy subject to Section 10965.03 issued, amended, or renewed on or after January 1, 2024, or an individual or small group policy issued, amended, or renewed on or after January 1, 2025, shall not impose a cost-sharing requirement for sexually transmitted infections screening, or for any items and services that are integral to a screening, under this section, Section 10112.2, or Section 10123.208, regardless of any of the following:
(1)The location of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting.
(2)The screening test, testing method or algorithm, or method of sample collection or processing.
(3)The identity or qualifications of the individual who collected or processed a sample.
(4)The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
(d)(1)A health insurer shall directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. If a nonparticipating essential community provider does not generate the results of screening, the provider shall submit the samples to a participating processing laboratory. A nonparticipating essential community provider shall not bill or collect any cost-sharing amounts from an insured for a sexually transmitted infections screening, or for integral items and services, under this section, Section 10112.2, or Section 10123.208.
(2)For items and services rendered subject to this section, unless otherwise agreed to by a nonparticipating essential community provider and the health insurer, the insurer shall reimburse an essential community provider the greater of its average contracted rate or 125 percent of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered.
(e)For purposes of this section:
(1)Average contracted rate means the average of the contracted commercial rates paid by the health insurer for the same or similar items or services in the geographic region.
(2)Essential community provider means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchanges Essential Community Provider List.
(3)General geographic region has the same meaning as provided by Section 10112.82 and the regulations promulgated thereunder.
(4)Gender has the same meaning as in Section 10140 and any regulations promulgated thereunder.
(5)Gender expression has the same meaning as in Section 10140 and any regulations promulgated thereunder.
(6)Utilization review has the same meaning as defined by Section 10144.52 and any regulations promulgated thereunder.
(f)This section does not apply to a specialized health insurance policy that does not cover an essential health benefit, as defined by Section 10112.27. If a health insurance policy is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible on sexually transmitted infections screening, or on integral items and services, under this section, Section 10112.2, or Section 10123.208, unless not applying the deductible would conflict with federal requirements for high deductible health plans.
(g)The delayed implementation of subdivisions (a) and (c) with respect to individual and small group health insurance policies does not excuse a health insurer from complying with Section 10112.2. An individual or small group health insurance policy issued, amended, or renewed on or after January 1, 2024, shall comply with the coverage and cost-sharing requirements for sexually transmitted infections screening under Section 10112.2.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A group or individual health care service plan contract shall, at a minimum, provide coverage for, and shall not impose any cost-sharing requirements for, any of the following:
(1)Evidence-based items or services that have in effect a rating of A or B in the recommendations of the United States Preventive Services Task Force, as periodically updated.
(2)Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention with respect to the individual involved.
(3)With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the United States Health Resources and Services Administration.
(4)With respect to women, those additional preventive care and screenings not described in paragraph (1) as provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration for purposes of this paragraph.
(5)For the purposes of this section:
(A)The current recommendations of the United States Preventive Services Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current, not including those issued in or around November 2009.
(B)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by this subdivision, or for any items or services that are integral to the provision of an item or service that is required by this subdivision, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by this subdivision.
(i)Integral item or service means an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this subdivision.
(ii)Current, generally accepted standard of care or clinical practice means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention, and product labeling approved by the United States Food and Drug Administration.
(b)This section does not prohibit a health care service plan from doing either of the following:
(1)Providing coverage for preventive items or services in addition to those required by subdivision (a).
(2)Denying coverage for services that are not recommended by the United States Preventive Services Task Force, except as provided by subdivision (d).
(c)A health care service plan shall provide coverage pursuant to subdivision (a) for plan years that begin on or after the date that is one year after the date that a novel recommendation or guideline is issued. A health care service plan shall provide coverage for modified or upgraded recommendations or guidelines pursuant to subdivision (a) no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
(1)A health care service plan that is required to provide coverage for any items and services specified in a recommendation or guideline described in subdivision (a) on the first day of a plan year shall provide coverage through the last day of the plan year, even if the recommendation or guideline changes or is no longer described in subdivision (a) during the plan year.
(2)Notwithstanding paragraph (1), if a recommendation or guideline described in paragraph (1) of subdivision (a) that was in effect on the first day of a plan year is downgraded to a D rating, or if any item or service associated with any recommendation or guideline specified in subdivision (a) is subject to a safety recall or is otherwise determined to pose a significant safety concern by a federal agency authorized to regulate the item or service during a plan year, a health care service plan is not required to cover the item or service through the last day of the plan year.
(d)(1)A health care service plan contract shall cover items and services pursuant to this section in accordance with an any applicable requirement of this chapter, including, but not limited to, Sections 1342.74 on prophylaxis of HIV infection, 1367.0021 on sexually transmitted infections screening, 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021 on home test kits for sexually transmitted diseases, and 1367.668 on colorectal cancer screening.
(2)Notwithstanding paragraph (1), Section 1367.25 shall exclusively govern the coverage of contraceptive drugs, devices, and products pursuant to this chapter.
(e)This section does not apply to a health care service plan contract that is a grandfathered health plan, or to a specialized health care service plan that does not cover an essential health benefit, as defined in Section 1367.005. The cost-sharing requirements of this section shall only apply to a health savings account-eligible health care service plan to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(f)The department shall coordinate with the Department of Insurance if it adopts regulations to implement this section.
SEC. 2.Section 1367.0021 is added to the Health and Safety Code, to read:1367.0021.(a)In addition to the items and services that are required by Section 1367.002, a group or individual large group health care service plan contract issued, amended, or renewed on or after January 1, 2024, or an individual or small group contract issued, amended, or renewed on or after January 1, 2025, shall not impose a cost-sharing requirement on a sexually transmitted infections screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) in the most recently updated version of its Sexually Transmitted Infections Treatment Guidelines or as most recently recommended by the CDC in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the United States Preventive Services Task Force conflicts with that of the CDC, or omits a CDC screening recommendation, a health care service plan contract shall not require any cost sharing for a sexually transmitted infections screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDCs recommendation.
(b)Notwithstanding Section 2713 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-13), a health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not require or impose any of the following for coverage of sexually transmitted infections screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
(1)Prior authorization or other utilization review requirements.
(2)Limits on frequency, method, treatment, or setting.
(3)Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
(4)Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
(5)Any other limits on the coverage or provision of sexually transmitted infections screening as a preventive item or service under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice, as prohibited by this chapter.
(c)A large group health care service plan contract issued, amended, or renewed on or after January 1, 2024, or an individual or small group contract issued, amended, or renewed on or after January 1, 2025, shall not impose a cost-sharing requirement for sexually transmitted infections screening, or for any items and services that are integral to a screening, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, regardless of any of the following:
(1)The location of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting.
(2)The screening test, testing method or algorithm, or method of sample collection or processing.
(3)The identity or qualifications of the individual who collected or processed a sample.
(4)The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
(d)(1)A health care service plan shall directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. If a nonparticipating essential community provider does not generate the results of screening, the provider shall submit the samples to a participating processing laboratory. A nonparticipating essential community provider shall not bill or collect any cost-sharing amounts from an enrollee for a sexually transmitted infections screening, or for integral items and services, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021.
(2)For items and services rendered subject to this section, unless otherwise agreed to by a nonparticipating essential community provider and the health care service plan, the plan shall reimburse an essential community provider the greater of its average contracted rate or 125 percent of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered.
(e)For purposes of this section:
(1)Average contracted rate means the average of the contracted commercial rates paid by the health care service plan for the same or similar items or services in the geographic region.
(2)Essential community provider means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchanges Essential Community Provider List.
(3)General geographic region has the same meaning as provided by Section 1371.31 and the regulations promulgated thereunder.
(4)Gender means sex, including gender identity and gender expression.
(5)Gender expression means gender-related appearance and behavior, whether or not stereotypically associated with assigned sex at birth.
(6)Utilization review has the same meaning as defined by Section 1374.721 and any regulations promulgated thereunder.
(f)This section does not apply to a specialized health care service plan contract that does not cover an essential health benefit, as defined by Section 1367.005. If a health care service plan contract is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible on sexually transmitted infections screening, or on integral items and services, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, unless not applying the deductible would conflict with federal requirements for high deductible health plans.
(g)The delayed implementation of subdivisions (a) and (c) for individual and small group health care service plan contracts does not excuse compliance with Section 1367.002. An individual or small group health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall comply with the coverage and cost-sharing requirements for sexually transmitted infections screening under Section 1367.002.
SEC. 3.Section 10112.2 of the Insurance Code is amended to read:10112.2.(a)A group or individual health insurance policy shall, at a minimum, provide coverage for, and shall not impose any cost-sharing requirements for, any of the following:
(1)Evidence-based items or services that have in effect a rating of A or B in the recommendations of the United States Preventive Services Task Force, as periodically updated.
(2)Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention with respect to the individual involved.
(3)With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the United States Health Resources and Services Administration.
(4)With respect to women, those additional preventive care and screenings not described in paragraph (1) as provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration for purposes of this paragraph.
(5)For the purposes of this section:
(A)The current recommendations of the United States Preventive Services Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current, not including those issued in or around November 2009.
(B)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by this subdivision, or for any items or services that are integral to the provision of an item or service that is required by this subdivision, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by this subdivision.
(i)Integral item or service means an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this subdivision.
(ii)Current, generally accepted standard of care or clinical practice means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention, and product labeling approved by the United States Food and Drug Administration.
(b)This section does not prohibit a health insurer from doing either of the following:
(1)Providing coverage for services in addition to those required by subdivision (a).
(2)Denying coverage for services that are not recommended by the United States Preventive Services Task Force, except as provided by subdivision (d).
(c)A health insurer shall provide coverage pursuant to subdivision (a) for policy years that begin on or after the date that is one year after the date that a novel recommendation or guideline is issued. A health insurer shall provide coverage for modified or upgraded recommendations or guidelines pursuant to subdivision (a) no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
(1)A health insurer that is required to provide coverage for any items and services specified in a recommendation or guideline described in subdivision (a) on the first day of a policy year shall provide coverage through the last day of the policy year, even if the recommendation or guideline changes or is no longer described in subdivision (a) during the policy year.
(2)Notwithstanding paragraph (1), if a recommendation or guideline described in paragraph (1) of subdivision (a) that was in effect on the first day of a policy year is downgraded to a D rating, or if any item or service associated with any recommendation or guideline specified in subdivision (a) is subject to a safety recall or is otherwise determined to pose a significant safety concern by a federal agency authorized to regulate the item or service during a policy year, a health insurer is not required to cover the item or service through the last day of the policy year.
(d)(1)A health insurance policy shall cover items and services pursuant to this section in accordance with an any applicable requirement of this part, including, but not limited to, Sections 10112.20 on sexually transmitted infections screening, 10123.1933 on prophylaxis of HIV infection, 10123.207 on colorectal cancer screening, and 10123.208 on home test kits for sexually transmitted diseases.
(2)Notwithstanding paragraph (1), Section 10123.196 shall exclusively govern the coverage of contraceptive drugs, devices, and products pursuant to this part.
(e)This section does not apply to a health insurance policy that is a grandfathered health plan, or to a specialized health insurance policy that does not cover an essential health benefit, as defined in Section 10112.27. The cost-sharing requirements of this section shall only apply to a health savings account-eligible health insurance policy to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(f)The department shall coordinate with the Department of Managed Health Care if it adopts regulations to implement this section.
(g)The commissioner and department may exercise the authority provided by this code and the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340), Chapter 4.5 (commencing with Section 11400), and Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code) to implement and enforce this section and all related sections, including those referenced herein. If the commissioner assesses a civil penalty for a violation, any hearing that is requested by the insurer shall be conducted by an administrative law judge of the Administrative Hearing Bureau of the department under the formal procedure of Chapter 5. This subdivision does not impair or restrict the commissioners authority pursuant to another provision of this code or the Administrative Procedure Act.
SEC. 4.Section 10112.20 is added to the Insurance Code, immediately following Section 10112.2, to read:10112.20.(a)In addition to the items and services that are required by Section 10112.2, a group or individual large group health insurance policy or policy subject to Section 10965.03 issued, amended, or renewed on or after January 1, 2024, or an individual or small group policy issued, amended, or renewed on or after January 1, 2025, shall not impose a cost-sharing requirement on a sexually transmitted infections screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) in the most recently updated version of its Sexually Transmitted Infections Treatment Guidelines or as most recently recommended by the CDC in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the United States Preventive Services Task Force conflicts with that of the CDC, or omits a CDC screening recommendation, a health insurance policy shall not require any cost sharing for a sexually transmitted infections screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDCs recommendation.
(b)Notwithstanding Section 2713 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-13), a health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not require or impose any of the following for coverage of sexually transmitted infections screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
(1)Prior authorization or other utilization review requirements.
(2)Limits on frequency, method, treatment, or setting.
(3)Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
(4)Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
(5)Any other limits on the coverage or provision of sexually transmitted infections screening as a preventive item or service under this section, Section 10112.2, or Section 10123.208, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this chapter.
(c)A large group health insurance policy or policy subject to Section 10965.03 issued, amended, or renewed on or after January 1, 2024, or an individual or small group policy issued, amended, or renewed on or after January 1, 2025, shall not impose a cost-sharing requirement for sexually transmitted infections screening, or for any items and services that are integral to a screening, under this section, Section 10112.2, or Section 10123.208, regardless of any of the following:
(1)The location of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting.
(2)The screening test, testing method or algorithm, or method of sample collection or processing.
(3)The identity or qualifications of the individual who collected or processed a sample.
(4)The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
(d)(1)A health insurer shall directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. If a nonparticipating essential community provider does not generate the results of screening, the provider shall submit the samples to a participating processing laboratory. A nonparticipating essential community provider shall not bill or collect any cost-sharing amounts from an insured for a sexually transmitted infections screening, or for integral items and services, under this section, Section 10112.2, or Section 10123.208.
(2)For items and services rendered subject to this section, unless otherwise agreed to by a nonparticipating essential community provider and the health insurer, the insurer shall reimburse an essential community provider the greater of its average contracted rate or 125 percent of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered.
(e)For purposes of this section:
(1)Average contracted rate means the average of the contracted commercial rates paid by the health insurer for the same or similar items or services in the geographic region.
(2)Essential community provider means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchanges Essential Community Provider List.
(3)General geographic region has the same meaning as provided by Section 10112.82 and the regulations promulgated thereunder.
(4)Gender has the same meaning as in Section 10140 and any regulations promulgated thereunder.
(5)Gender expression has the same meaning as in Section 10140 and any regulations promulgated thereunder.
(6)Utilization review has the same meaning as defined by Section 10144.52 and any regulations promulgated thereunder.
(f)This section does not apply to a specialized health insurance policy that does not cover an essential health benefit, as defined by Section 10112.27. If a health insurance policy is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible on sexually transmitted infections screening, or on integral items and services, under this section, Section 10112.2, or Section 10123.208, unless not applying the deductible would conflict with federal requirements for high deductible health plans.
(g)The delayed implementation of subdivisions (a) and (c) with respect to individual and small group health insurance policies does not excuse a health insurer from complying with Section 10112.2. An individual or small group health insurance policy issued, amended, or renewed on or after January 1, 2024, shall comply with the coverage and cost-sharing requirements for sexually transmitted infections screening under Section 10112.2.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A group or individual health care service plan contract shall, at a minimum, provide coverage for, and shall not impose any cost-sharing requirements for, any of the following:
(1)Evidence-based items or services that have in effect a rating of A or B in the recommendations of the United States Preventive Services Task Force, as periodically updated.
(2)Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention with respect to the individual involved.
(3)With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the United States Health Resources and Services Administration.
(4)With respect to women, those additional preventive care and screenings not described in paragraph (1) as provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration for purposes of this paragraph.
(5)For the purposes of this section:
(A)The current recommendations of the United States Preventive Services Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current, not including those issued in or around November 2009.
(B)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by this subdivision, or for any items or services that are integral to the provision of an item or service that is required by this subdivision, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by this subdivision.
(i)Integral item or service means an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this subdivision.
(ii)Current, generally accepted standard of care or clinical practice means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention, and product labeling approved by the United States Food and Drug Administration.
(b)This section does not prohibit a health care service plan from doing either of the following:
(1)Providing coverage for preventive items or services in addition to those required by subdivision (a).
(2)Denying coverage for services that are not recommended by the United States Preventive Services Task Force, except as provided by subdivision (d).
(c)A health care service plan shall provide coverage pursuant to subdivision (a) for plan years that begin on or after the date that is one year after the date that a novel recommendation or guideline is issued. A health care service plan shall provide coverage for modified or upgraded recommendations or guidelines pursuant to subdivision (a) no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
(1)A health care service plan that is required to provide coverage for any items and services specified in a recommendation or guideline described in subdivision (a) on the first day of a plan year shall provide coverage through the last day of the plan year, even if the recommendation or guideline changes or is no longer described in subdivision (a) during the plan year.
(2)Notwithstanding paragraph (1), if a recommendation or guideline described in paragraph (1) of subdivision (a) that was in effect on the first day of a plan year is downgraded to a D rating, or if any item or service associated with any recommendation or guideline specified in subdivision (a) is subject to a safety recall or is otherwise determined to pose a significant safety concern by a federal agency authorized to regulate the item or service during a plan year, a health care service plan is not required to cover the item or service through the last day of the plan year.
(d)(1)A health care service plan contract shall cover items and services pursuant to this section in accordance with an applicable requirement of this chapter, including including, but not limited to, Sections 1342.74 on prophylaxis of HIV infection, 1367.0021 on sexually transmitted infections screening, 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021 on home test kits for sexually transmitted diseases, and 1367.668 on colorectal cancer screening.
(2)Notwithstanding paragraph (1), Section 1367.25 shall exclusively govern the coverage of contraceptive drugs, devices, and products pursuant to this chapter.
(e)This section does not apply to a health care service plan contract that is a grandfathered health plan, or to a specialized health care service plan that does not cover an essential health benefit, as defined in Section 1367.005. The cost-sharing requirements of this section shall only apply to a health savings account-eligible health care service plan to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(f)The department shall coordinate with the Department of Insurance if it adopts regulations to implement this section.
SEC. 2.Section 1367.0021 is added to the Health and Safety Code, to read:1367.0021.(a)In addition to the items and services that are required by Section 1367.002, a group or individual health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement on a sexually transmitted infections screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) in the most recently updated version of its Sexually Transmitted Infections Treatment Guidelines, as subsequently modified by any published updates Guidelines or as most recently recommended by the CDC in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the United States Preventive Services Task Force conflicts with that of the CDC, or omits a CDC screening recommendation, a health care service plan contract shall not require any cost sharing for a sexually transmitted infections screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDCs recommendation.
(b)Notwithstanding Section 2713 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-13), a health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not require or impose any of the following for coverage of sexually transmitted infections screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
(1)Prior authorization or other utilization review requirements.
(2)Limits on frequency, method, treatment, or setting.
(3)Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
(4)Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
(5)Any other limits on the coverage or provision of sexually transmitted infections screening as a preventive item or service under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice practice, as prohibited by this chapter.
(c)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement for sexually transmitted infections screening, or for any items and services that are integral to a screening, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, regardless of any of the following:
(1)The location of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting.
(2)The screening test, testing method or algorithm, or method of sample collection or processing.
(3)The identity or qualifications of the individual who collected or processed a sample.
(4)The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
(d)(1)A health care service plan shall directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. If a nonparticipating essential community provider does not generate the results of screening, the provider shall submit the samples to a participating processing laboratory. A nonparticipating essential community provider shall not bill or collect any cost-sharing amounts from an enrollee for a sexually transmitted infections screening, or for integral items and services, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021.
(2)For items and services rendered subject to this section, unless otherwise agreed to by a nonparticipating essential community provider and the health care service plan, the plan shall reimburse an essential community provider the greater of its average contracted rate or 125 percent of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered.
(e)For purposes of this section:
(1)Average contracted rate means the average of the contracted commercial rates paid by the health care service plan for the same or similar items or services in the geographic region.
(2)Essential community provider means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchanges Essential Community Provider List.
(3)General geographic region has the same meaning as provided by Section 1371.31 and the regulations promulgated thereunder.
(4)Gender means sex, including gender identity and gender expression.
(5)Gender expression means gender-related appearance and behavior, whether or not stereotypically associated with assigned sex at birth.
(6)Utilization review has the same meaning as defined by Section 1374.721 and any regulations promulgated thereunder.
(f)This section does not apply to a specialized health care service plan contract that does not cover an essential health benefit, as defined by Section 1367.005. If a health care service plan contract is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible on sexually transmitted infections screening, or on integral items and services, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, unless not applying the deductible would conflict with federal requirements for high deductible health plans.
SEC. 3.Section 10112.2 of the Insurance Code is amended to read:10112.2.(a)A group or individual health insurance policy shall, at a minimum, provide coverage for, and shall not impose any cost-sharing requirements for, any of the following:
(1)Evidence-based items or services that have in effect a rating of A or B in the recommendations of the United States Preventive Services Task Force, as periodically updated.
(2)Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention with respect to the individual involved.
(3)With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the United States Health Resources and Services Administration.
(4)With respect to women, those additional preventive care and screenings not described in paragraph (1) as provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration for purposes of this paragraph.
(5)For the purposes of this section:
(A)The current recommendations of the United States Preventive Services Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current, not including those issued in or around November 2009.
(B)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by this subdivision, or for any items or services that are integral to the provision of an item or service that is required by this subdivision, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by this subdivision.
(i)Integral item or service means an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this subdivision.
(ii)Current, generally accepted standard of care or clinical practice means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention, and product labeling approved by the United States Food and Drug Administration.
(b)This section does not prohibit a health insurer from doing either of the following:
(1)Providing coverage for services in addition to those required by subdivision (a).
(2)Denying coverage for services that are not recommended by the United States Preventive Services Task Force, except as provided by subdivision (d).
(c)A health insurer shall provide coverage pursuant to subdivision (a) for policy years that begin on or after the date that is one year after the date that a novel recommendation or guideline is issued. A health insurer shall provide coverage for modified or upgraded recommendations or guidelines pursuant to subdivision (a) no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
(1)A health insurer that is required to provide coverage for any items and services specified in a recommendation or guideline described in subdivision (a) on the first day of a policy year shall provide coverage through the last day of the policy year, even if the recommendation or guideline changes or is no longer described in subdivision (a) during the policy year.
(2)Notwithstanding paragraph (1), if a recommendation or guideline described in paragraph (1) of subdivision (a) that was in effect on the first day of a policy year is downgraded to a D rating, or if any item or service associated with any recommendation or guideline specified in subdivision (a) is subject to a safety recall or is otherwise determined to pose a significant safety concern by a federal agency authorized to regulate the item or service during a policy year, a health insurer is not required to cover the item or service through the last day of the policy year.
(d)(1)A health insurance policy shall cover items and services pursuant to this section in accordance with an applicable requirement of this part, including including, but not limited to, Sections 10112.20 on sexually transmitted infections screening, 10123.1933 on prophylaxis of HIV infection, 10123.207 on colorectal cancer screening, and 10123.208 on home test kits for sexually transmitted diseases.
(2)Notwithstanding paragraph (1), Section 10123.196 shall exclusively govern the coverage of contraceptive drugs, devices, and products pursuant to this part.
(e)This section does not apply to a health insurance policy that is a grandfathered health plan, or to a specialized health insurance policy that does not cover an essential health benefit, as defined in Section 10112.27. The cost-sharing requirements of this section shall only apply to a health savings account-eligible health insurance policy to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(f)The department shall coordinate with the Department of Managed Health Care if it adopts regulations to implement this section.
(g)The commissioner and department may exercise the authority provided by this code and the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340), Chapter 4.5 (commencing with Section 11400), and Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code) to implement and enforce this section and all related sections, including those referenced herein. If the commissioner assesses a civil penalty for a violation, any hearing that is requested by the insurer shall be conducted by an administrative law judge of the Administrative Hearing Bureau of the department under the formal procedure of Chapter 5. This subdivision does not impair or restrict the commissioners authority pursuant to another provision of this code or the Administrative Procedure Act.
SEC. 4.Section 10112.20 is added to the Insurance Code, immediately following Section 10112.2, to read:10112.20.(a)In addition to the items and services that are required by Section 10112.2, a group or individual health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement on a sexually transmitted infections screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) in the most recently updated version of its Sexually Transmitted Infections Treatment Guidelines, as subsequently modified by any published updates Guidelines or as most recently recommended by the CDC in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the United States Preventive Services Task Force conflicts with that of the CDC, or omits a CDC screening recommendation, a health insurance policy shall not require any cost sharing for a sexually transmitted infections screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDCs recommendation.
(b)Notwithstanding Section 2713 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-13), a health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not require or impose any of the following for coverage of sexually transmitted infections screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
(1)Prior authorization or other utilization review requirements.
(2)Limits on frequency, method, treatment, or setting.
(3)Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
(4)Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
(5)Any other limits on the coverage or provision of sexually transmitted infections screening as a preventive item or service under this section, Section 10112.2, or Section 10123.208, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this chapter.
(c)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement for sexually transmitted infections screening, or for any items and services that are integral to a screening, under this section, Section 10112.2, or Section 10123.208, regardless of any of the following:
(1)The location of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting.
(2)The screening test, testing method or algorithm, or method of sample collection or processing.
(3)The identity or qualifications of the individual who collected or processed a sample.
(4)The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
(d)(1)A health insurer shall directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. If a nonparticipating essential community provider does not generate the results of screening, the provider shall submit the samples to a participating processing laboratory. A nonparticipating essential community provider shall not bill or collect any cost sharing cost-sharing amounts from an insured for a sexually transmitted infections screening, or for integral items and services, under this section, Section 10112.2, or Section 10123.208.
(2)For items and services rendered subject to this section, unless otherwise agreed to by a nonparticipating essential community provider and the health insurer, the insurer shall reimburse an essential community provider the greater of its average contracted rate or 125 percent of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered.
(e)For purposes of this section:
(1)Average contracted rate means the average of the contracted commercial rates paid by the health insurer for the same or similar items or services in the geographic region.
(2)Essential community provider means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchanges Essential Community Provider List.
(3)General geographic region has the same meaning as provided by Section 10112.82 and the regulations promulgated thereunder.
(4)Gender has the same meaning as in Section 10140 and any regulations promulgated thereunder.
(5)Gender expression has the same meaning as in Section 10140 and any regulations promulgated thereunder.
(6)Utilization review has the same meaning as defined by Section 10144.52 and any regulations promulgated thereunder.
(f)This section does not apply to a specialized health insurance policy that does not cover an essential health benefit, as defined by Section 10112.27. If a health insurance policy is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible on sexually transmitted infections screening, or on integral items and services, under this section, Section 10112.2, or Section 10123.208, unless not applying the deductible would conflict with federal requirements for high deductible health plans.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A group or individual health care service plan contract shall, at a minimum, provide coverage for, and shall not impose any cost-sharing requirements for, any of the following:
(1)Evidence-based items or services that have in effect a rating of A or B in the recommendations of the United States Preventive Services Task Force, as periodically updated.
(2)Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention with respect to the individual involved.
(3)With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the United States Health Resources and Services Administration.
(4)With respect to women, those additional preventive care and screenings not described in paragraph (1) as provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration for purposes of this paragraph.
(5)For the purposes of this section:
(A)The current recommendations of the United States Preventive Services Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current, not including those issued in or around November 2009.
(B)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by this subdivision, or for any items or services that are integral to the provision of an item or service that is required by this subdivision, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by this subdivision.
(i)Integral item or service means an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this subdivision.
(ii)Current, generally accepted standard of care or clinical practice means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention, and product labeling approved by the United States Food and Drug Administration.
(b)This section does not prohibit a health care service plan from doing either of the following:
(1)Providing coverage for preventive items or services in addition to those required by subdivision (a).
(2)Denying coverage for services that are not recommended by the United States Preventive Services Task Force, except as provided by subdivision (d).
(c)A health care service plan shall provide coverage pursuant to subdivision (a) for plan years that begin on or after the date that is one year after the date that a novel recommendation or guideline is issued. A health care service plan shall provide coverage for modified or upgraded recommendations or guidelines pursuant to subdivision (a) no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
(1)A health care service plan that is required to provide coverage for any items and services specified in a recommendation or guideline described in subdivision (a) on the first day of a plan year shall provide coverage through the last day of the plan year, even if the recommendation or guideline changes or is no longer described in subdivision (a) during the plan year.
(2)Notwithstanding paragraph (1), if a recommendation or guideline described in paragraph (1) of subdivision (a) that was in effect on the first day of a plan year is downgraded to a D rating, or if any item or service associated with any recommendation or guideline specified in subdivision (a) is subject to a safety recall or is otherwise determined to pose a significant safety concern by a federal agency authorized to regulate the item or service during a plan year, a health care service plan is not required to cover the item or service through the last day of the plan year.
(d)(1)A health care service plan contract shall cover items and services pursuant to this section in accordance with an applicable requirement of this chapter, including Sections 1342.74 on prophylaxis of HIV infection, 1367.0021 on sexually transmitted infections screening, 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021 on home test kits for sexually transmitted diseases, and 1367.668 on colorectal cancer screening.
(2)Notwithstanding paragraph (1), Section 1367.25 shall exclusively govern the coverage of contraceptive drugs, devices, and products pursuant to this chapter.
(e)This section does not apply to a health care service plan contract that is a grandfathered health plan, or to a specialized health care service plan that does not cover an essential health benefit, as defined in Section 1367.005. The cost-sharing requirements of this section shall only apply to a health savings account-eligible health care service plan to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(f)The department shall coordinate with the Department of Insurance if it adopts regulations to implement this section.
SEC. 2.Section 1367.0021 is added to the Health and Safety Code, to read:1367.0021.(a)In addition to the items and services that are required by Section 1367.002, a group or individual health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement on a sexually transmitted infections screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) in the most recently updated version of its Sexually Transmitted Infections Treatment Guidelines, as subsequently modified by any published updates in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the United States Preventive Services Task Force conflicts with that of the CDC, or omits a CDC screening recommendation, a health care service plan contract shall not require any cost sharing for a sexually transmitted infections screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDCs recommendation.
(b)Notwithstanding Section 2713 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-13), a health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not require or impose any of the following for coverage of sexually transmitted infections screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
(1)Prior authorization or other utilization review requirements.
(2)Limits on frequency, method, treatment, or setting.
(3)Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
(4)Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
(5)Any other limits on the coverage or provision of sexually transmitted infections screening as a preventive item or service under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this chapter.
(c)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement for sexually transmitted infections screening, or for any items and services that are integral to a screening, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, regardless of any of the following:
(1)The location of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting.
(2)The screening test, testing method or algorithm, or method of sample collection or processing.
(3)The identity or qualifications of the individual who collected or processed a sample.
(4)The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
(d)(1)A health care service plan shall directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening its median contracted rate in the general geographic region for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. If a nonparticipating essential community provider does not generate the results of screening, the provider shall submit the samples to a participating processing laboratory. A nonparticipating essential community provider shall not bill or collect any cost-sharing amounts from an enrollee for a sexually transmitted infections screening, or for integral items and services, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021.
(2)For items and services rendered subject to this section, unless otherwise agreed to by a nonparticipating essential community provider and the health care service plan, the plan shall reimburse an essential community provider the greater of its average contracted rate or 125 percent of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered.
(e)For purposes of this section:
(1)Average contracted rate means the average of the contracted commercial rates paid by the health care service plan for the same or similar items or services in the geographic region.
(1)(2)Essential community provider means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchanges Essential Community Provider List.
(2)(3)General geographic region has the same meaning as provided by Section 1371.31 and the regulations promulgated thereunder.
(3)(4)Gender means sex, including gender identity and gender expression.
(4)(5)Gender expression means gender-related appearance and behavior, whether or not stereotypically associated with assigned sex at birth.
(5)(6)Utilization review has the same meaning as defined by Section 1374.721 and any regulations promulgated thereunder.
(f)This section does not apply to a specialized health care service plan contract that does not cover an essential health benefit, as defined by Section 1367.005. If a health care service plan contract is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible on sexually transmitted infections screening, or on integral items and services, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, unless not applying the deductible would conflict with federal requirements for high deductible health plans.
SEC. 3.Section 10112.2 of the Insurance Code is amended to read:10112.2.(a)A group or individual health insurance policy shall, at a minimum, provide coverage for, and shall not impose any cost-sharing requirements for, any of the following:
(1)Evidence-based items or services that have in effect a rating of A or B in the recommendations of the United States Preventive Services Task Force, as periodically updated.
(2)Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention with respect to the individual involved.
(3)With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the United States Health Resources and Services Administration.
(4)With respect to women, those additional preventive care and screenings not described in paragraph (1) as provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration for purposes of this paragraph.
(5)For the purposes of this section:
(A)The current recommendations of the United States Preventive Services Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current, not including those issued in or around November 2009.
(B)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by this subdivision, or for any items or services that are integral to the provision of an item or service that is required by this subdivision, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by this subdivision.
(i)Integral item or service means an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this subdivision.
(ii)Current, generally accepted standard of care or clinical practice means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention, and product labeling approved by the United States Food and Drug Administration.
(b)This section does not prohibit a health insurer from doing either of the following:
(1)Providing coverage for services in addition to those required by subdivision (a).
(2)Denying coverage for services that are not recommended by the United States Preventive Services Task Force, except as provided by subdivision (d).
(c)A health insurer shall provide coverage pursuant to subdivision (a) for policy years that begin on or after the date that is one year after the date that a novel recommendation or guideline is issued. A health insurer shall provide coverage for modified or upgraded recommendations or guidelines pursuant to subdivision (a) no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
(1)A health insurer that is required to provide coverage for any items and services specified in a recommendation or guideline described in subdivision (a) on the first day of a policy year shall provide coverage through the last day of the policy year, even if the recommendation or guideline changes or is no longer described in subdivision (a) during the policy year.
(2)Notwithstanding paragraph (1), if a recommendation or guideline described in paragraph (1) of subdivision (a) that was in effect on the first day of a policy year is downgraded to a D rating, or if any item or service associated with any recommendation or guideline specified in subdivision (a) is subject to a safety recall or is otherwise determined to pose a significant safety concern by a federal agency authorized to regulate the item or service during a policy year, a health insurer is not required to cover the item or service through the last day of the policy year.
(d)(1)A health insurance policy shall cover items and services pursuant to this section in accordance with an applicable requirement of this part, including Sections 10112.20 on sexually transmitted infections screening, 10123.1933 on prophylaxis of HIV infection, 10123.207 on colorectal cancer screening, and 10123.208 on home test kits for sexually transmitted diseases.
(2)Notwithstanding paragraph (1), Section 10123.196 shall exclusively govern the coverage of contraceptive drugs, devices, and products pursuant to this part.
(e)This section does not apply to a health insurance policy that is a grandfathered health plan, or to a specialized health insurance policy that does not cover an essential health benefit, as defined in Section 10112.27. The cost-sharing requirements of this section shall only apply to a health savings account-eligible health insurance policy to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(f)The department shall coordinate with the Department of Managed Health Care if it adopts regulations to implement this section.
(g)The commissioner and department may exercise the authority provided by this code and the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340), Chapter 4.5 (commencing with Section 11400), and Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code) to implement and enforce this section and all related sections, including those referenced herein. If the commissioner assesses a civil penalty for a violation, any hearing that is requested by the insurer shall be conducted by an administrative law judge of the Administrative Hearing Bureau of the department under the formal procedure of Chapter 5. This subdivision does not impair or restrict the commissioners authority pursuant to another provision of this code or the Administrative Procedure Act.
SEC. 4.Section 10112.20 is added to the Insurance Code, immediately following Section 10112.2, to read:10112.20.(a)In addition to the items and services that are required by Section 10112.2, a group or individual health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement on a sexually transmitted infections screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) in the most recently updated version of its Sexually Transmitted Infections Treatment Guidelines, as subsequently modified by any published updates in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the United States Preventive Services Task Force conflicts with that of the CDC, or omits a CDC screening recommendation, a health insurance policy shall not require any cost sharing for a sexually transmitted infections screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDCs recommendation.
(b)Notwithstanding Section 2713 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg-13), a health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not require or impose any of the following for coverage of sexually transmitted infections screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
(1)Prior authorization or other utilization review requirements.
(2)Limits on frequency, method, treatment, or setting.
(3)Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
(4)Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
(5)Any other limits on the coverage or provision of sexually transmitted infections screening as a preventive item or service under this section, Section 10112.2, or Section 10123.208, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this chapter.
(c)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement for sexually transmitted infections screening, or for any items and services that are integral to a screening, under this section, Section 10112.2, or Section 10123.208, regardless of any of the following:
(1)The location of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting.
(2)The screening test, testing method or algorithm, or method of sample collection or processing.
(3)The identity or qualifications of the individual who collected or processed a sample.
(4)The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
(d)(1)A health insurer shall directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening its median contracted rate in the general geographic region for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. If a nonparticipating essential community provider does not generate the results of screening, the provider shall submit the samples to a participating processing laboratory. A nonparticipating essential community provider shall not bill or collect any cost sharing amounts from an insured for a sexually transmitted infections screening, or for integral items and services, under this section, Section 10112.2, or Section 10123.208.
(2)For items and services rendered subject to this section, unless otherwise agreed to by a nonparticipating essential community provider and the health insurer, the insurer shall reimburse an essential community provider the greater of its average contracted rate or 125 percent of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered.
(e)For purposes of this section:
(1)Average contracted rate means the average of the contracted commercial rates paid by the health insurer for the same or similar items or services in the geographic region.
(1)(2)Essential community provider means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchanges Essential Community Provider List.
(2)(3)General geographic region has the same meaning as provided by Section 10112.82 and the regulations promulgated thereunder.
(3)(4)Gender has the same meaning as in Section 10140 and any regulations promulgated thereunder.
(4)(5)Gender expression has the same meaning as in Section 10140 and any regulations promulgated thereunder.
(5)(6)Utilization review has the same meaning as defined by Section 10144.52 and any regulations promulgated thereunder.
(f)This section does not apply to a specialized health insurance policy that does not cover an essential health benefit, as defined by Section 10112.27. If a health insurance policy is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible on sexually transmitted infections screening, or on integral items and services, under this section, Section 10112.2, or Section 10123.208, unless not applying the deductible would conflict with federal requirements for high deductible health plans.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A group or individual health care service plan contract shall, at a minimum, provide coverage for, and shall not impose any cost-sharing requirements for, any of the following:
(1)Evidence-based items or services that have in effect a rating of A or B in the recommendations of the United States Preventive Services Task Force, as periodically updated.
(2)Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention with respect to the individual involved.
(3)With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the United States Health Resources and Services Administration.
(4)With respect to women, those additional preventive care and screenings not described in paragraph (1) as provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration for purposes of this paragraph.
(5)For the purposes of this section:
(A)The current recommendations of the United States Preventive Services Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current, not including those issued in or around November 2009.
(B)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by this subdivision, or for any items or services that are integral to the provision of an item or service that is required by this subdivision, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by this subdivision.
(i)Integral item or service means an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this subdivision.
(ii)Current, generally accepted standard of care or clinical practice means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention, and product labeling approved by the United States Food and Drug Administration.
(b)This section does not prohibit a health care service plan from doing either of the following:
(1)Providing coverage for preventive items or services in addition to those required by subdivision (a).
(2)Denying coverage for services that are not recommended by the United States Preventive Services Task Force, except as provided by subdivision (d).
(c)A health care service plan shall provide coverage pursuant to subdivision (a) for plan years that begin on or after the date that is one year after the date that a novel recommendation or guideline is issued. A health care service plan shall provide coverage for modified or upgraded recommendations or guidelines pursuant to subdivision (a) no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
(1)A health care service plan that is required to provide coverage for any items and services specified in a recommendation or guideline described in subdivision (a) on the first day of a plan year shall provide coverage through the last day of the plan year, even if the recommendation or guideline changes or is no longer described in subdivision (a) during the plan year.
(2)Notwithstanding paragraph (1), if a recommendation or guideline described in paragraph (1) of subdivision (a) that was in effect on the first day of a plan year is downgraded to a D rating, or if any item or service associated with any recommendation or guideline specified in subdivision (a) is subject to a safety recall or is otherwise determined to pose a significant safety concern by a federal agency authorized to regulate the item or service during a plan year, a health care service plan is not required to cover the item or service through the last day of the plan year.
(d)(1)A health care service plan contract shall cover items and services pursuant to this section in accordance with an applicable requirement of this chapter, including Sections 1342.74 on prophylaxis of HIV infection, 1367.0021 on sexually transmitted infections screening, 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021 on home test kits for sexually transmitted diseases, and 1367.668 on colorectal cancer screening.
(2)Notwithstanding paragraph (1), Section 1367.25 shall exclusively govern the coverage of contraceptive drugs, devices, and products pursuant to this chapter.
(e)This section does not apply to a health care service plan contract that is a grandfathered health plan, or to a specialized health care service plan that does not cover an essential health benefit, as defined in Section 1367.005. The cost-sharing requirements of this section shall only apply to a health savings account-eligible health care service plan to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(f)The department shall coordinate with the Department of Insurance if it adopts regulations to implement this section.
SEC. 2.Section 1367.0021 is added to the Health and Safety Code, to read:1367.0021.(a)In addition to the items and services that are required by Section 1367.002, a group or individual health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement on a sexually transmitted infections screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) in the most recently updated version of its Sexually Transmitted Infections Treatment Guidelines, as subsequently modified by any published updates in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the United States Preventive Services Task Force conflicts with that of the CDC, or omits a CDC screening recommendation, a health care service plan contract shall not require any cost sharing for a sexually transmitted infections screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDCs recommendation.
(b)Notwithstanding Section 2713 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg), 300gg-13), a health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not require or impose any of the following for coverage of sexually transmitted infections screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
(1)Prior authorization or other utilization review requirements.
(2)Limits on frequency, method, treatment, or setting.
(3)Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
(4)Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
(5)Any other limits on the coverage or provision of sexually transmitted infections screening as a preventive item or service under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this chapter.
(c)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement for sexually transmitted infections screening, or for any items and services that are integral to a screening, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, regardless of any of the following:
(1)The location or method of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting.
(2)The screening test, testing method or algorithm, or method of sample collection or processing.
(3)The identity or qualifications of the individual who collected or processed a sample.
(4)The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
(d)A health care service plan shall directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening its median contracted rate in the general geographic region for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. If a nonparticipating essential community provider does not generate the results of screening, the provider shall submit the samples to a participating processing laboratory. A nonparticipating essential community provider shall not bill or collect any cost-sharing amounts from an enrollee for a sexually transmitted infections screening, or for integral items and services, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021.
(e)For purposes of this section:
(1)Essential community provider means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchanges Essential Community Provider List.
(2)General geographic region has the same meaning as provided by Section 1371.31 and the regulations promulgated thereunder.
(3)Gender means sex, including gender identity and gender expression.
(4)Gender expression means gender-related appearance and behavior, whether or not stereotypically associated with assigned sex at birth.
(5)Utilization review has the same meaning as defined by Section 1374.721 and any regulations promulgated thereunder.
(f)This section does not apply to a specialized health care service plan contract that does not cover an essential health benefit, as defined by Section 1367.005. If a health care service plan contract is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible on sexually transmitted infections screening, or on integral items and services, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, unless not applying the deductible would conflict with federal requirements for high deductible health plans.
SEC. 3.Section 10112.2 of the Insurance Code is amended to read:10112.2.(a)A group or individual health insurance policy shall, at a minimum, provide coverage for, and shall not impose any cost-sharing requirements for, any of the following:
(1)Evidence-based items or services that have in effect a rating of A or B in the recommendations of the United States Preventive Services Task Force, as periodically updated.
(2)Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention with respect to the individual involved.
(3)With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the United States Health Resources and Services Administration.
(4)With respect to women, those additional preventive care and screenings not described in paragraph (1) as provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration for purposes of this paragraph.
(5)For the purposes of this section:
(A)The current recommendations of the United States Preventive Services Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current, not including those issued in or around November 2009.
(B)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by this subdivision, or for any items or services that are integral to the provision of an item or service that is required by this subdivision, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by this subdivision.
(i)Integral item or service means an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this subdivision.
(ii)Current, generally accepted standard of care or clinical practice means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention, and product labeling approved by the United States Food and Drug Administration.
(b)This section does not prohibit a health insurer from doing either of the following:
(1)Providing coverage for services in addition to those required by subdivision (a).
(2)Denying coverage for services that are not recommended by the United States Preventive Services Task Force, except as provided by subdivision (d).
(c)A health insurer shall provide coverage pursuant to subdivision (a) for policy years that begin on or after the date that is one year after the date that a novel recommendation or guideline is issued. A health insurer shall provide coverage for modified or upgraded recommendations or guidelines pursuant to subdivision (a) no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
(1)A health insurer that is required to provide coverage for any items and services specified in a recommendation or guideline described in subdivision (a) on the first day of a policy year shall provide coverage through the last day of the policy year, even if the recommendation or guideline changes or is no longer described in subdivision (a) during the policy year.
(2)Notwithstanding paragraph (1), if a recommendation or guideline described in paragraph (1) of subdivision (a) that was in effect on the first day of a policy year is downgraded to a D rating, or if any item or service associated with any recommendation or guideline specified in subdivision (a) is subject to a safety recall or is otherwise determined to pose a significant safety concern by a federal agency authorized to regulate the item or service during a policy year, a health insurer is not required to cover the item or service through the last day of the policy year.
(d)(1)A health insurance policy shall cover items and services pursuant to this section in accordance with an applicable requirement of this part, including Sections 10112.20 on sexually transmitted infections screening, 10123.1933 on prophylaxis of HIV infection, 10123.207 on colorectal cancer screening, and 10123.208 on home test kits for sexually transmitted diseases.
(2)Notwithstanding paragraph (1), Section 10123.196 shall exclusively govern the coverage of contraceptive drugs, devices, and products pursuant to this part.
(e)This section does not apply to a health insurance policy that is a grandfathered health plan, or to a specialized health insurance policy that does not cover an essential health benefit, as defined in Section 10112.27. The cost-sharing requirements of this section shall only apply to a health savings account-eligible health insurance policy to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(f)The department shall coordinate with the Department of Managed Health Care if it adopts regulations to implement this section.
(g)The commissioner and department may exercise the authority provided by this code and the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340), Chapter 4.5 (commencing with Section 11400), and Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code) to implement and enforce this section and all related sections, including those referenced herein. If the commissioner assesses a civil penalty for a violation, any hearing that is requested by the insurer shall be conducted by an administrative law judge of the Administrative Hearing Bureau of the department under the formal procedure of Chapter 5. This subdivision does not impair or restrict the commissioners authority pursuant to another provision of this code or the Administrative Procedure Act.
SEC. 4.Section 10112.20 is added to the Insurance Code, immediately following Section 10112.2, to read:10112.20.(a)In addition to the items and services that are required by Section 10112.2, a group or individual health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement on a sexually transmitted infections screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) in the most recently updated version of its Sexually Transmitted Infections Treatment Guidelines, as subsequently modified by any published updates in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the United States Preventive Services Task Force conflicts with that of the CDC, or omits a CDC screening recommendation, a health insurance policy shall not require any cost sharing for a sexually transmitted infections screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDCs recommendation.
(b)Notwithstanding Section 2713 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg), 300gg-13), a health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not require or impose any of the following for coverage of sexually transmitted infections screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
(1)Prior authorization or other utilization review requirements.
(2)Limits on frequency, method, treatment, or setting.
(3)Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
(4)Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
(5)Any other limits on the coverage or provision of sexually transmitted infections screening as a preventive item or service under this section, Section 10112.2, or Section 10123.208, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this chapter.
(c)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement for sexually transmitted infections screening, or for any items and services that are integral to a screening, under this section, Section 10112.2, or Section 10123.208, regardless of any of the following:
(1)The location or method of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting.
(2)The screening test, testing method or algorithm, or method of sample collection or processing.
(3)The identity or qualifications of the individual who collected or processed a sample.
(4)The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
(d)A health insurer shall directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening its median contracted rate in the general geographic region for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. If a nonparticipating essential community provider does not generate the results of screening, the provider shall submit the samples to a participating processing laboratory. A nonparticipating essential community provider shall not bill or collect any cost sharing amounts from an insured for a sexually transmitted infections screening, or for integral items and services, under this section, Section 10112.2, or Section 10123.208.
(e)For purposes of this section:
(1)Essential community provider means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchanges Essential Community Provider List.
(2)General geographic region has the same meaning as provided by Section 10112.82 and the regulations promulgated thereunder.
(3)Gender means sex, including gender identity and gender expression.(4)Gender expression means gender-related appearance and behavior, whether or not stereotypically associated with assigned sex at birth.(3)Gender has the same meaning as in Section 10140 and any regulations promulgated thereunder.
(4)Gender expression has the same meaning as in Section 10140 and any regulations promulgated thereunder.
(5)Utilization review has the same meaning as defined by Section 10144.52 and any regulations promulgated thereunder.
(f)This section does not apply to a specialized health insurance policy that does not cover an essential health benefit, as defined by Section 10112.27. If a health insurance policy is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible on sexually transmitted infections screening, or on integral items and services, under this section, Section 10112.2, or Section 10123.208, unless not applying the deductible would conflict with federal requirements for high deductible health plans.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A group or individual nongrandfathered health care service plan contract shall, at a minimum, provide coverage for for, and shall not impose any cost-sharing requirements for for, any of the following:
(1)Evidence-based items or services that have in effect a rating of A or B in the recommendations of the United States Preventive Services Task Force, as periodically updated.
(2)Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention with respect to the individual involved.
(3)With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the United States Health Resources and Services Administration.
(4)With respect to women, those additional preventive care and screenings not described in paragraph (1) as provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration for purposes of this paragraph.
(5)For the purposes of this section, the section:
(A)The current recommendations of the United States Preventive Services Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current other than current, not including those issued in or around November 2009.
(B)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by this subdivision, or for any items or services that are integral to the provision of an item or service that is required by this subdivision, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by this subdivision.
(i)Integral item or service means an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this subdivision.
(ii)Current, generally accepted standard of care or clinical practice means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention, and product labeling approved by the United States Food and Drug Administration.
(b)This section does not prohibit a health care service plan contract from providing from doing either of the following:
(1)Providing coverage for preventive items or services in addition to those recommended by the United States Preventive Services Task Force or to deny required by subdivision (a).
(2)Denying coverage for services that are not recommended by the United States Preventive Services Task Force. Force, except as provided by subdivision (d).
(c)A health care service plan shall provide coverage pursuant to subdivision (a) for plan years that begin on or after the date that is one year after the date the that a novel recommendation or guideline is issued. A health care service plan shall provide coverage for modified or upgraded recommendations or guidelines pursuant to subdivision (a) no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
(1)A health care service plan that is required to provide coverage for any items and services specified in a recommendation or guideline described in subdivision (a) on the first day of a plan year shall provide coverage through the last day of the plan year, even if the recommendation or guideline changes or is no longer described in subdivision (a) during the plan year.
(2)Notwithstanding paragraph (1), if a recommendation or guideline described in paragraph (1) of subdivision (a) that was in effect on the first day of a plan year is downgraded to a D rating, or if any item or service associated with any recommendation or guideline specified in subdivision (a) is subject to a safety recall or is otherwise determined to pose a significant safety concern by a federal agency authorized to regulate the item or service during a plan year, a health care service plan is not required to cover the item or service through the last day of the plan year.
(d)(1)A health care service plan contract shall cover items and services pursuant to this section in accordance with an applicable requirement of this chapter, including Sections 1342.74 on prophylaxis of HIV infection, 1367.0021 on sexually transmitted infections screening, 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021 on home test kits for sexually transmitted diseases, and 1367.668 on colorectal cancer screening.
(2)Notwithstanding paragraph (1), Section 1367.25 shall exclusively govern the coverage of contraceptive drugs, devices, and products pursuant to this chapter.
(d)(e)This section does not apply to a health care service plan contract that is a grandfathered health plan, or to a specialized health care service plan that does not cover an essential health benefit, as defined in Section 1367.005. This The cost-sharing requirements of this section shall only apply to a health savings account-eligible health care service plan to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(e)(f)The department shall coordinate with the Department of Insurance if it adopts regulations to implement this section.
SEC. 2.Section 1367.0021 is added to the Health and Safety Code, to read:1367.0021.(a)In addition to the items and services that are required by Section 1367.002, a group or individual health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement on a sexually transmitted infections screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) in the most recently updated version of its Sexually Transmitted Infections Treatment Guidelines, as subsequently modified by any published updates in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the United States Preventive Services Task Force conflicts with that of the CDC, or omits a CDC screening recommendation, a health care service plan contract shall not require any cost sharing for a sexually transmitted infections screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDCs recommendation.
(b)Notwithstanding Section 2713 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg), a health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not require or impose any of the following for coverage of sexually transmitted infections screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
(1)Prior authorization or other utilization review requirements.
(2)Limits on frequency, method, treatment, or setting.
(3)Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
(4)Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
(5)Any other limits on the coverage or provision of sexually transmitted infections screening as a preventive item or service under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this chapter.
(c)A health care service plan contract issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement for sexually transmitted infections screening, or for any items and services that are integral to a screening, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, regardless of any of the following:
(1)The location or method of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting.
(2)The screening test, testing method or algorithm, or method of sample collection or processing.
(3)The identity or qualifications of the individual who collected or processed a sample.
(4)The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
(d)A health care service plan shall directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening its median contracted rate in the general geographic region for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. If a nonparticipating essential community provider does not generate the results of screening, the provider shall submit the samples to a participating processing laboratory. A nonparticipating essential community provider shall not bill or collect any cost-sharing amounts from an enrollee for a sexually transmitted infections screening, or for integral items and services, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021.
(e)For purposes of this section:
(1)Essential community provider means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchanges Essential Community Provider List.
(2)General geographic region has the same meaning as provided by Section 1371.31 and the regulations promulgated thereunder.
(3)Gender means sex, including gender identity and gender expression.
(4)Gender expression means gender-related appearance and behavior, whether or not stereotypically associated with assigned sex at birth.
(5)Utilization review has the same meaning as defined by Section 1374.721 and any regulations promulgated thereunder.
(f)This section does not apply to a specialized health care service plan contract that does not cover an essential health benefit, as defined by Section 1367.005. If a health care service plan contract is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible on sexually transmitted infections screening, or on integral items and services, under this section, Section 1367.002, or Section 1367.34 as added by Section 3 of Chapter 486 of the Statutes of 2021, unless not applying the deductible would conflict with federal requirements for high deductible health plans.
SEC. 3.Section 10112.2 of the Insurance Code is amended to read:10112.2.(a)A group or individual nongrandfathered health insurance policy shall, at a minimum, provide coverage for for, and shall not impose any cost-sharing requirements for for, any of the following:
(1)Evidence-based items or services that have in effect a rating of A or B in the recommendations of the United States Preventive Services Task Force, as periodically updated.
(2)Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention with respect to the individual involved.
(3)With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the United States Health Resources and Services Administration.
(4)With respect to women, those additional preventive care and screenings not described in paragraph (1) as provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration for purposes of this paragraph.
(5)For the purposes of this section, the section:
(A)The current recommendations of the United States Preventive Services Task Force regarding breast cancer screening, mammography, and prevention shall be considered the most current other than current, not including those issued in or around November 2009.
(B)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by this subdivision, or for any items or services that are integral to the provision of an item or service that is required by this subdivision, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by this subdivision.
(i)Integral item or service means an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this subdivision.
(ii)Current, generally accepted standard of care or clinical practice means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention, and product labeling approved by the United States Food and Drug Administration.
(b)This section does not prohibit a health insurance policy from providing insurer from doing either of the following:
(1)Providing coverage for services in addition to those recommended by the United States Preventive Services Task Force or to deny required by subdivision (a).
(2)Denying coverage for services that are not recommended by the United States Preventive Services Task Force. Force, except as provided by subdivision (d).
(c)A health insurer shall provide coverage pursuant to subdivision (a) for policy years that begin on or after the date that is one year after the date the that a novel recommendation or guideline is issued. A health insurer shall provide coverage for modified or upgraded recommendations or guidelines pursuant to subdivision (a) no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
(1)A health insurer that is required to provide coverage for any items and services specified in a recommendation or guideline described in subdivision (a) on the first day of a policy year shall provide coverage through the last day of the policy year, even if the recommendation or guideline changes or is no longer described in subdivision (a) during the policy year.
(2)Notwithstanding paragraph (1), if a recommendation or guideline described in paragraph (1) of subdivision (a) that was in effect on the first day of a policy year is downgraded to a D rating, or if any item or service associated with any recommendation or guideline specified in subdivision (a) is subject to a safety recall or is otherwise determined to pose a significant safety concern by a federal agency authorized to regulate the item or service during a policy year, a health insurer is not required to cover the item or service through the last day of the policy year.
(d)(1)A health insurance policy shall cover items and services pursuant to this section in accordance with an applicable requirement of this part, including Sections 10112.20 on sexually transmitted infections screening, 10123.1933 on prophylaxis of HIV infection, 10123.207 on colorectal cancer screening, and 10123.208 on home test kits for sexually transmitted diseases.
(2)Notwithstanding paragraph (1), Section 10123.196 shall exclusively govern the coverage of contraceptive drugs, devices, and products pursuant to this part.
(d)(e)This section does not apply to a health insurance policy that is a grandfathered health plan, or to a specialized health insurance policy that does not cover an essential health benefit, as defined in Section 10112.27. This The cost-sharing requirements of this section shall only apply to a health savings account-eligible health insurance policy to the extent it does not fail to be treated as a high deductible health insurance policy plan under Section 223 of Title 26 of the United States Code.
(e)(f)The department shall coordinate with the Department of Managed Health Care if it adopts regulations to implement this section.
(g)The commissioner and department may exercise the authority provided by this code and the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340), Chapter 4.5 (commencing with Section 11400), and Chapter 5 (commencing with Section 11500) of Part 1 of Division 3 of Title 2 of the Government Code) to implement and enforce this section and all related sections, including those referenced herein. If the commissioner assesses a civil penalty for a violation, any hearing that is requested by the insurer shall be conducted by an administrative law judge of the Administrative Hearing Bureau of the department under the formal procedure of Chapter 5. This subdivision does not impair or restrict the commissioners authority pursuant to another provision of this code or the Administrative Procedure Act.
SEC. 4.Section 10112.20 is added to the Insurance Code, immediately following Section 10112.2, to read:10112.20.(a)In addition to the items and services that are required by Section 10112.2, a group or individual health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement on a sexually transmitted infections screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) in the most recently updated version of its Sexually Transmitted Infections Treatment Guidelines, as subsequently modified by any published updates in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the United States Preventive Services Task Force conflicts with that of the CDC, or omits a CDC screening recommendation, a health insurance policy shall not require any cost sharing for a sexually transmitted infections screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDCs recommendation.
(b)Notwithstanding Section 2713 of the federal Public Health Service Act (42 U.S.C. Sec. 300gg), a health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not require or impose any of the following for coverage of sexually transmitted infections screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
(1)Prior authorization or other utilization review requirements.
(2)Limits on frequency, method, treatment, or setting.
(3)Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
(4)Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
(5)Any other limits on the coverage or provision of sexually transmitted infections screening as a preventive item or service under this section, Section 10112.2, or Section 10123.208, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this chapter.
(c)A health insurance policy issued, amended, or renewed on or after January 1, 2024, shall not impose a cost-sharing requirement for sexually transmitted infections screening, or for any items and services that are integral to a screening, under this section, Section 10112.2, or Section 10123.208, regardless of any of the following:
(1)The location or method of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting.
(2)The screening test, testing method or algorithm, or method of sample collection or processing.
(3)The identity or qualifications of the individual who collected or processed a sample.
(4)The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
(d)A health insurer shall directly reimburse a nonparticipating provider or facility of sexually transmitted infections screening its median contracted rate in the general geographic region for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. If a nonparticipating essential community provider does not generate the results of screening, the provider shall submit the samples to a participating processing laboratory. A nonparticipating essential community provider shall not bill or collect any cost sharing amounts from an insured for a sexually transmitted infections screening, or for integral items and services, under this section, Section 10112.2, or Section 10123.208.
(e)For purposes of this section:
(1)Essential community provider means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchanges Essential Community Provider List.
(2)General geographic region has the same meaning as provided by Section 10112.82 and the regulations promulgated thereunder.
(3)Gender means sex, including gender identity and gender expression.
(4)Gender expression means gender-related appearance and behavior, whether or not stereotypically associated with assigned sex at birth.
(5)Utilization review has the same meaning as defined by Section 10144.52 and any regulations promulgated thereunder.
(f)This section does not apply to a specialized health insurance policy that does not cover an essential health benefit, as defined by Section 10112.27. If a health insurance policy is a high deductible health plan under the definition set forth in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible on sexually transmitted infections screening, or on integral items and services, under this section, Section 10112.2, or Section 10123.208, unless not applying the deductible would conflict with federal requirements for high deductible health plans.
SEC. 5.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Jan 29, 2024 | Consideration of Governor's veto stricken from file. |
| Jan 3, 2024 | Consideration of Governor's veto pending. |
| Oct 7, 2023 | Vetoed by Governor. |
| Sep 21, 2023 | Enrolled and presented to the Governor at 3:30 p.m. |
| Sep 13, 2023 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 64. Noes 8. Page 3378.). |
| Sep 12, 2023 | In Assembly. Concurrence in Senate amendments pending. |
| Sep 12, 2023 | Read third time. Passed. Ordered to the Assembly. (Ayes 31. Noes 7. Page 2621.). |
| Sep 5, 2023 | Read second time. Ordered to third reading. |
| Sep 1, 2023 | From committee: Do pass. (Ayes 5. Noes 2.) (September 1). |
| Aug 14, 2023 | In committee: Referred to APPR suspense file. |
| Jul 13, 2023 | Read second time and amended. Re-referred to Com. on APPR. |
| Jul 13, 2023 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 10. Noes 1.) (July 12). |
| Jul 3, 2023 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| Jun 14, 2023 | Referred to Com. on HEALTH. |
| Jun 1, 2023 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 31, 2023 | Read third time. Passed. Ordered to the Senate. (Ayes 64. Noes 10. Page 2039.) |
| May 18, 2023 | Read second time. Ordered to third reading. |
| May 18, 2023 | From committee: Do pass. (Ayes 11. Noes 2.) (May 18). |
| May 18, 2023 | Joint Rule 62(a), file notice suspended. (Page 1580.) |
| May 17, 2023 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| May 2, 2023 | Re-referred to Com. on APPR. |
| May 1, 2023 | Read second time and amended. |
| Apr 27, 2023 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 12. Noes 0.) (April 25). |
| Mar 21, 2023 | Re-referred to Com. on HEALTH. |
| Mar 20, 2023 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Mar 9, 2023 | Referred to Com. on HEALTH. |
| Feb 18, 2023 | From printer. May be heard in committee March 20. |
| Feb 17, 2023 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 13, 2023 | AB 1645 Zbur Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Sep 12, 2023 | Assembly 3rd Reading AB1645 Zbur By Eggman | Senate Floor |
Passed |
|
| Sep 1, 2023 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Aug 14, 2023 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jul 12, 2023 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| May 31, 2023 | AB 1645 Zbur Assembly Third Reading | Assembly Floor |
Passed |
|
| May 18, 2023 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 25, 2023 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Aids Healthcare Foundation | ** Support | |
| America'S Health Insurance Plans | ** Against | |
| APLA Health | ** Support | |
| Asian Liver Center At Stanford University | ** Support | |
| Association Of California Life & Health Insurance Companies | ** Against | |
| Bienestar Human Services | ** Support | |
| California Association Of Health Plans | ** Against | |
| California Chamber Of Commerce | ** Against | |
| California Department of Insurance | ** Support | |
| California Hepatitis Alliance | ** Support | |
| California LGBTQ Health and Human Services Network | ** Support | |
| California Life Sciences | ** Support | |
| California School-Based Health Alliance | ** Support | |
| California Transcends | ** Support | |
| Citizens for Choice | ** Support | |
| City of Long Beach | ** Support | |
| Color Health, Inc. | ** Support | |
| Community Clinic Association of Los Angeles County | ** Support | |
| County of Los Angeles Board of Supervisors | ** Support | |
| Department Of Finance | ** Against | |
| End Hep C San Francisco | ** Support | |
| End the Epidemics | ** Support | |
| Equality California | ** Support | |
| Essential Access Health | ** Support | |
| Gender Spectrum | ** Support | |
| Glide | ** Support | |
| Health Access California | ** Support | |
| Hep B Free - San Francisco Bay Area | ** Support | |
| Insurance Commissioner Ricardo Lara | ** Support | |
| Justice in Aging | ** Support | |
| Los Angeles LGBT Center | ** Support | |
| Lyon-Martin Community Health | ** Support | |
| Lyon-Martin Health Services | ** Support | |
| National Health Law Program | ** Support | |
| Planned Parenthood Affiliates Of California | ** Support | |
| Positive Images LGBTQIAL+ Center | ** Support | |
| Radiant Health Centers | ** Support | |
| San Diego Pride | ** Support | |
| San Francisco Aids Foundation | ** Support | |
| SF Hep B Free - Bay Area | ** Support | |
| Somos Familia Valle | ** Support | |
| Source LGBT+ Center | ** Support | |
| The Women's Building | ** Support | |
| Trans Youth Liberation | ** Support | |
| Venice Family Clinic | ** Support | |
| Viet Rainbow of Orange County | ** Support | |
| Western Center on Law & Poverty, INC. | ** Support |
GOVERNOR'S VETO
GV Bill Id:AB 1645
Author:(Zbur)
As Enrolled Ver:September 18, 2023
2/3 vote
SUMMARY
Prohibits a large group health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, or an individual or small group contract or policy issued, amended, or renewed on or after January 1, 2025, from imposing a cost-sharing requirement for office visits of specified preventive care services and screenings and for items or services that are integral to their provision. Prohibits health plan contracts and insurance policies from imposing a cost-sharing requirement, utilization review, or other specified limits on a recommended sexually transmitted infections (STI) screening, and from imposing a cost-sharing requirement for any items and services integral to a STI screening, as specified. Requires a health plan or insurer to directly reimburse specified nonparticipating providers or facilities of STI screening, specified rates (unless otherwise agreed to by a nonparticipating essential community provider (ECP) and the health plan or insurer, the greater of its average contracted rate or 125% of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered) for screening tests and integral items and services rendered, and prohibits the nonparticipating provider from billing or collecting a cost-sharing amount for a STI screening from an enrollee or insured.
Senate Amendments
Delay implementation for individual or small group contracts or policies. Clarify that the delayed implementation for individual and small group health care service plan contracts does not excuse compliance with existing preventive law and requires compliance with the coverage and cost-sharing requirements, as specified.
Governor’s Veto Message
This bill would prohibit health plans from imposing cost sharing for specified preventive or screening services and associated office visits and would require plans to directly reimburse nonparticipating ECPs for STI screenings and services.
I appreciate the author's efforts to increase access to preventive health care, including human immunodeficiency virus (HIV) and STI testing, colorectal screening, and other services. However, components of this proposal depart from structures in federal and state law, such as the existing policies for reimbursement to non-contracted providers. Further, because this bill exceeds the cost-sharing provisions under the Affordable Care Act (ACA), it would result in increased costs to health plans passed on to consumers through premiums. The State must weigh the potential benefits of all new mandates with the comprehensive costs to the entire delivery system.
COMMENTS
The California Health Benefits Review Program (CHBRP) writes that preventive services are services such as screening tests and counseling that aim to prevent illness and disease. Preventive services recommended are required to be covered without cost-sharing initially required by the ACA and later codified in AB 306 (Pan), Chapter 486, Statutes of 2021. CHBRP's analysis states that this bill amends California's preventive services mandate as follows:
- Under existing law:
- For commercial/CalPERS enrollees in nongrandfathered California Department of Insurance (CDI)-regulated policies and Department of Managed Health Care (DMHC)-regulated plans:
- Prohibits cost sharing for preventative items and services recommended by the ACA – beginning in the plan or policy year that follows publication of the recommendation.
- Allows a deductible for enrollees in health savings account (HSA) qualified high deductible health plan (HDHP) if not applying the deductible would disqualify the plan as a federally recognized HSA-HDHP.
- For commercial/CalPERS enrollees in nongrandfathered California Department of Insurance (CDI)-regulated policies and Department of Managed Health Care (DMHC)-regulated plans:
- This bill amends existing law to:
- Make compliance in no less than 90 days required for modified or upgraded preventive service recommendations (but not for new recommendations).
- Prohibit cost sharing for office visits and/or any item or service associated with provision of the referenced preventative items and services.
- Specify required compliance with existing California mandates that also address preventive services.
- This bill establishes a STI screening mandate to:
- For commercial/CalPERS enrollees in all CDI-regulated policies and DMHC-regulated plans grandfathered and nongrandfathered:
- Prohibits the application of cost sharing to coverage for STI screening – unless not applying the deductible for an enrollee in an HSA-HDHP would disqualify the plan as a federally recognized HSA-HDHP.
- Add the CDC STI screening recommendations to this list of preventive services referenced in coverage mandates in California and prohibit cost sharing for coverage for STI screenings or any related items or services, regardless of:
- The location or method of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting;
- The screening test, testing method or algorithm, or method of sample collection or processing;
- The identity or qualifications of the individual who collected or processed a sample; and,
- The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
- When accessed through an ECP listed on the Exchange's ECP, or when accessed through a participating provider, prohibit, for coverage of STI screenings and for any related items:
- Prior authorization or other utilization review requirements;
- Limits on frequency, method, treatment, or setting;
- Limits on confirmatory or post-treatment retesting of an asymptomatic patient;
- Limits based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening;
- Any other limits on the coverage or provision of STI screening as a preventive item or service under this section or other mandates related to STI screening, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this this bill.
- Requires that nonparticipating ECPs be reimbursed at the median contracted rate in the general geographic region
- For commercial/CalPERS enrollees in all CDI-regulated policies and DMHC-regulated plans grandfathered and nongrandfathered:
- CHBRP analysis. CHBRP states the following in its analysis of this bill: Impact on expenditures. According to CHBRP, this bill would increase total net annual expenditures by $20,065,000, or 0.0136%, for enrollees with DMHC-regulated plans and CDI-regulated policies. The increase in total health insurance premiums paid by employers and enrollees for newly covered benefits is adjusted by a net decrease in cost sharing and enrollee expenses for covered and/or noncovered benefits.
Increases in premiums as a result of this bill would vary by market segment. CHBRP notes that such changes are related to the number of enrollees with health insurance that would be subject to this bill. Per member per month (PMPM) premium increases range from a high of 0.0912% in DMHC-regulated grandfathered small-group plans to a low of 0.0085% in CDI-regulated Individual other nongrandfathered policies. For enrollees associated with CalPERS in DMHC-regulated plans, the PMPM premium increase would be 0.0504%. For Medi-Cal beneficiaries enrolled in DMHC-regulated plans, there is no impact.
According to the Author
Every Californian deserves access to preventive health care that is comprehensive, inclusive, and affordable. Current California law relating to preventive health care and screenings for STIs contains loopholes that need closing. The author concludes that this bill ensures that patients can access not only preventive care but also all of the services and office visits that are necessary for delivering that care without cost-sharing, including medication management and lab testing for preexposure prophylaxis (PrEP), a life-saving HIV prevention medication.
Arguments in Support
Equality California writes this bill will ensure that patients can access lifesaving preventive care – including all the services and office visits that are necessary for delivering that care – without cost sharing. This bill will also expand access to screening for STIs and help to address the state's growing STI epidemic among California youth, LGBTQ+ people, and communities of color. On March 30, 2023, a Texas federal judge issued a ruling in the case, Braidwood Management v. Becerra, striking down part of the ACA requiring no cost coverage of preventive services recommended or updated by the US Preventive Services Task Force. The federal government is currently appealing the decision. While California law will continue to require that all state-regulated health plans cover preventive services without cost sharing, there are loopholes that need closing. This bill will strengthen existing law in the face of these incessant judicial attacks on the ACA and ensure that health plans cover the full spectrum of preventive services without cost sharing, including office visits and other necessary health care services for delivering a preventive benefit. This bill will codify longstanding federal guidance that health plans must cover services that are 'integral' to preventive care – including anesthesia and polyp removal during a colonoscopy; placement, management, and removal of longacting reversible contraceptives; and lab testing for HIV PrEP – without cost sharing, while further requiring coverage of integral services consistent with current clinical best practices. Additionally, this bill will eliminate loopholes that allow cost sharing for recommended preventive care benefits in some instances. Every Californian deserves access to preventive health care that is comprehensive, inclusive, and affordable.
Arguments in Opposition
The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America's Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. All ACA-compliant plans provide a robust package of essential health benefits (EHBs) in the large group, small business, and individual markets (both on and off the Exchange). In the individual market, the ACA sought to preserve the balance between comprehensive coverage and affordability by requiring states to bear the cost for new mandates that exceed the EHB package. The Centers for Medicaid and Medicare Services recently affirmed that states are still responsible for defraying the cost of new mandates. The opposition states mandate bills will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options. The Department of Finance is opposed to this bill, as it creates ongoing costs and pressures to the General Fund and Managed Care Fund, resulting from increased administrative costs for implementation and state-funded healthcare premiums. Additionally, the preventive services required under this bill exceeds the federal ACA. To the extent this bill results in additional assessments on health plans and insurers, consumers may face increased health care premiums.
FISCAL COMMENTS
According to the Senate Appropriations Committee, DMHC estimates costs of approximately $707,000 in 2023-24, $1,607,000 in 2024-25, and $1,619,000 in 2025-26 and annually thereafter for state administration (Managed Care Fund). CDI anticipates no fiscal impact. Unknown General Fund costs due to increased CalPERS health plan premiums.
VOTES
ASM HEALTH: 12-0-3
YES: Wood, Waldron, Aguiar-Curry, Arambula, Boerner, Wendy Carrillo, Maienschein, McCarty, Rodriguez, Santiago, Villapudua, Weber
ABS, ABST OR NV: Flora, Vince Fong, Joe Patterson
ASM APPROPRIATIONS: 11-2-3
YES: Holden, Bryan, Calderon, Wendy Carrillo, Mike Fong, Hart, Lowenthal, Papan, Pellerin, Weber, Ortega
NO: Megan Dahle, Dixon
ABS, ABST OR NV: Mathis, Robert Rivas, Sanchez
ASSEMBLY FLOOR: 64-10-6
YES: Addis, Aguiar-Curry, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Connolly, Mike Fong, Friedman, Gabriel, Garcia, Gipson, Grayson, Haney, Hart, Holden, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Rendon
NO: Alanis, Megan Dahle, Davies, Dixon, Essayli, Flora, Gallagher, Hoover, Jim Patterson, Ta
ABS, ABST OR NV: Chen, Vince Fong, Lackey, Mathis, Joe Patterson, Sanchez
SENATE FLOOR: 31-7-2
YES: Allen, Alvarado-Gil, Archuleta, Ashby, Atkins, Becker, Blakespear, Bradford, Cortese, Dodd, Durazo, Eggman, Glazer, Gonzalez, Hurtado, Laird, Limón, McGuire, Menjivar, Min, Newman, Padilla, Portantino, Roth, Rubio, Skinner, Smallwood-Cuevas, Stern, Umberg, Wahab, Wiener
NO: Dahle, Jones, Nguyen, Niello, Ochoa Bogh, Seyarto, Wilk
ABS, ABST OR NV: Caballero, Grove
ASSEMBLY FLOOR: 64-8-8
YES: Addis, Aguiar-Curry, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Connolly, Mike Fong, Friedman, Gabriel, Garcia, Gipson, Grayson, Haney, Hart, Holden, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Rendon, Reyes, Luz Rivas, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Robert Rivas
NO: Megan Dahle, Davies, Dixon, Essayli, Gallagher, Hoover, Jim Patterson, Ta
ABS, ABST OR NV: Alanis, Chen, Flora, Vince Fong, Lackey, Mathis, Joe Patterson, Sanchez
UPDATED
VERSION: September 18, 2023
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0002512
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 1645
Author:(Zbur)
As Amended Ver:July 13, 2023
Majority vote
SUMMARY
Prohibits a large group health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, or an individual or small group contract or policy issued, amended, or renewed on or after January 1, 2025, from imposing a cost-sharing requirement for office visits of specified preventive care services and screenings and for items or services that are integral to their provision. Prohibits health plan contracts and insurance policies from imposing a cost-sharing requirement, utilization review, or other specified limits on a recommended sexually transmitted infections (STI) screening, and from imposing a cost-sharing requirement for any items and services integral to a STI screening, as specified. Requires a health plan or insurer to directly reimburse specified nonparticipating providers or facilities of STI screening, specified rates (unless otherwise agreed to by a nonparticipating essential community provider (ECP) and the health plan or insurer, the greater of its average contracted rate or 125% of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered) for screening tests and integral items and services rendered, and prohibits the nonparticipating provider from billing or collecting a cost-sharing amount for a STI screening from an enrollee or insured.
Senate Amendments
Delay implementation for individual or small group contracts or policies. Clarify that the delayed implementation for individual and small group health care service plan contracts does not excuse compliance with existing preventive law and requires compliance with the coverage and cost-sharing requirements, as specified.
COMMENTS
The California Health Benefits Review Program (CHBRP) writes that preventive services are services such as screening tests and counseling that aim to prevent illness and disease. Preventive services recommended are required to be covered without cost-sharing initially required by the federal Patient Protection and Affordable Care Act (ACA) and later codified in AB 306 (Pan), Chapter 486, Statutes of 2021. CHBRP's analysis states that this bill amends California's preventive services mandate as follows:
- Under existing law:
- For commercial/CalPERS enrollees in nongrandfathered California Department of Insurance (CDI)-regulated policies and Department of Managed Health Care (DMHC)-regulated plans:
- Prohibits cost sharing for preventative items and services recommended by the ACA – beginning in the plan or policy year that follows publication of the recommendation.
- Allows a deductible for enrollees in health savings account (HSA) qualified high deductible health plan (HDHP) if not applying the deductible would disqualify the plan as a federally recognized HSA-HDHP.
- For commercial/CalPERS enrollees in nongrandfathered California Department of Insurance (CDI)-regulated policies and Department of Managed Health Care (DMHC)-regulated plans:
- This bill amends existing law to:
- Make compliance in no less than 90 days required for modified or upgraded preventive service recommendations (but not for new recommendations).
- Prohibit cost sharing for office visits and/or any item or service associated with provision of the referenced preventative items and services.
- Specify required compliance with existing California mandates that also address preventive services.
- This bill establishes a STI screening mandate to:
- For commercial/CalPERS enrollees in all CDI-regulated policies and DMHC-regulated plans grandfathered and nongrandfathered:
- Prohibits the application of cost sharing to coverage for STI screening – unless not applying the deductible for an enrollee in an HSA-HDHP would disqualify the plan as a federally recognized HSA-HDHP.
- Add the CDC STI screening recommendations to this list of preventive services referenced in coverage mandates in California and prohibit cost sharing for coverage for STI screenings or any related items or services, regardless of:
- The location or method of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting;
- The screening test, testing method or algorithm, or method of sample collection or processing;
- The identity or qualifications of the individual who collected or processed a sample; and,
- The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
- When accessed through an ECP listed on the Exchange's ECP, or when accessed through a participating provider, prohibit, for coverage of STI screenings and for any related items:
- Prior authorization or other utilization review requirements;
- Limits on frequency, method, treatment, or setting;
- Limits on confirmatory or post-treatment retesting of an asymptomatic patient;
- Limits based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening;
- Any other limits on the coverage or provision of STI screening as a preventive item or service under this section or other mandates related to STI screening, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this this bill.
- Requires that nonparticipating ECPs be reimbursed at the median contracted rate in the general geographic region
- For commercial/CalPERS enrollees in all CDI-regulated policies and DMHC-regulated plans grandfathered and nongrandfathered:
- CHBRP analysis. CHBRP states the following in its analysis of this bill: Impact on expenditures. According to CHBRP, this bill would increase total net annual expenditures by $20,065,000, or 0.0136%, for enrollees with DMHC-regulated plans and CDI-regulated policies. The increase in total health insurance premiums paid by employers and enrollees for newly covered benefits is adjusted by a net decrease in cost sharing and enrollee expenses for covered and/or noncovered benefits.
Increases in premiums as a result of this bill would vary by market segment. CHBRP notes that such changes are related to the number of enrollees with health insurance that would be subject to this bill. Per member per month (PMPM) premium increases range from a high of 0.0912% in DMHC-regulated grandfathered small-group plans to a low of 0.0085% in CDI-regulated Individual other nongrandfathered policies. For enrollees associated with CalPERS in DMHC-regulated plans, the PMPM premium increase would be 0.0504%. For Medi-Cal beneficiaries enrolled in DMHC-regulated plans, there is no impact.
According to the Author
Every Californian deserves access to preventive health care that is comprehensive, inclusive, and affordable. Current California law relating to preventive health care and screenings for STIs contains loopholes that need closing. The author concludes that this bill ensures that patients can access not only preventive care but also all of the services and office visits that are necessary for delivering that care without cost-sharing, including medication management and lab testing for preexposure prophylaxis (PrEP), a life-saving HIV prevention medication.
Arguments in Support
Equality California writes this bill will ensure that patients can access lifesaving preventive care – including all the services and office visits that are necessary for delivering that care – without cost sharing. This bill will also expand access to screening for STIs and help to address the state's growing STI epidemic among California youth, LGBTQ+ people, and communities of color. On March 30, 2023, a Texas federal judge issued a ruling in the case, Braidwood Management v. Becerra, striking down part of the ACA requiring no cost coverage of preventive services recommended or updated by the US Preventive Services Task Force. The federal government is currently appealing the decision. While California law will continue to require that all state-regulated health plans cover preventive services without cost sharing, there are loopholes that need closing. This bill will strengthen existing law in the face of these incessant judicial attacks on the ACA and ensure that health plans cover the full spectrum of preventive services without cost sharing, including office visits and other necessary health care services for delivering a preventive benefit. This bill will codify longstanding federal guidance that health plans must cover services that are 'integral' to preventive care – including anesthesia and polyp removal during a colonoscopy; placement, management, and removal of longacting reversible contraceptives; and lab testing for HIV PrEP – without cost sharing, while further requiring coverage of integral services consistent with current clinical best practices. Additionally, this bill will eliminate loopholes that allow cost sharing for recommended preventive care benefits in some instances. Every Californian deserves access to preventive health care that is comprehensive, inclusive, and affordable.
Arguments in Opposition
The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America's Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. All ACA-compliant plans provide a robust package of essential health benefits (EHBs) in the large group, small business, and individual markets (both on and off the Exchange). In the individual market, the ACA sought to preserve the balance between comprehensive coverage and affordability by requiring states to bear the cost for new mandates that exceed the EHB package. The Centers for Medicaid and Medicare Services recently affirmed that states are still responsible for defraying the cost of new mandates. The opposition states mandate bills will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options. The Department of Finance is opposed to this bill, as it creates ongoing costs and pressures to the General Fund and Managed Care Fund, resulting from increased administrative costs for implementation and state-funded healthcare premiums. Additionally, the preventive services required under this bill exceeds the federal ACA. To the extent this bill results in additional assessments on health plans and insurers, consumers may face increased health care premiums. Current law requires every health plan contract and insurance policy to provide coverage for home test kits for STIs that are deemed medically necessary. Every health plan contract and insurance policy must provide coverage without any cost-sharing for colorectal cancer screening. Current law also requires health plans and insurance policies to cover all [United States}Food and Drug Administration (FDA)-approved contraceptive drugs, devices, and other products, including coverage without a prescription and without cost-sharing for over-the-counter FDA-approved contraceptive drugs and products.
FISCAL COMMENTS
According to the Senate Appropriations Committee, DMHC estimates costs of approximately $707,000 in 2023-24, $1,607,000 in 2024-25, and $1,619,000 in 2025-26 and annually thereafter for state administration (Managed Care Fund). CDI anticipates no fiscal impact. Unknown General Fund costs due to increased CalPERS health plan premiums.
VOTES:
ASM HEALTH: 12-0-3
YES: Wood, Waldron, Aguiar-Curry, Arambula, Boerner, Wendy Carrillo, Maienschein, McCarty, Rodriguez, Santiago, Villapudua, Weber
ABS, ABST OR NV: Flora, Vince Fong, Joe Patterson
ASM APPROPRIATIONS: 11-2-3
YES: Holden, Bryan, Calderon, Wendy Carrillo, Mike Fong, Hart, Lowenthal, Papan, Pellerin, Weber, Ortega
NO: Megan Dahle, Dixon
ABS, ABST OR NV: Mathis, Robert Rivas, Sanchez
ASSEMBLY FLOOR: 64-10-6
YES: Addis, Aguiar-Curry, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Connolly, Mike Fong, Friedman, Gabriel, Garcia, Gipson, Grayson, Haney, Hart, Holden, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Rendon
NO: Alanis, Megan Dahle, Davies, Dixon, Essayli, Flora, Gallagher, Hoover, Jim Patterson, Ta
ABS, ABST OR NV: Chen, Vince Fong, Lackey, Mathis, Joe Patterson, Sanchez
UPDATED
VERSION: July 13, 2023
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0001711
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 1645 |
THIRD READING
Bill No: AB 1645
Author: Zbur (D)
Amended: 7/13/23 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 10-1, 7/12/23
AYES: Eggman, Glazer, Gonzalez, Hurtado, Limón, Menjivar, Roth, Rubio, Wahab, Wiener
NOES: Nguyen
NO VOTE RECORDED: Grove
SENATE APPROPRIATIONS COMMITTEE: 5-2, 9/1/23
AYES: Portantino, Ashby, Bradford, Wahab, Wiener
NOES: Jones, Seyarto
ASSEMBLY FLOOR: 64-10, 5/31/23 - See last page for vote
SUBJECT: Health care coverage: cost sharing
SOURCE: Insurance Commissioner Ricardo Lara
APLA Health
Equality California
Los Angeles LGBT Center
San Francisco AIDS Foundation
DIGEST:
This bill expands health insurance coverage for preventive services without cost-sharing to include office visits and services integral to the provision of the item or service, and requires coverage earlier than federal requirements. Prohibits a large group health plan contract or insurance policy issued, amended, or renewed on or after January 1, 2024, and a small group and individual market plan or policy issued, amended, or renewed on or after January 1, 2025 from imposing a cost-sharing requirement or prior authorization on a sexually transmitted infection screening that is recommended by the federal Centers for Disease Control and Prevention (CDC) or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory, and requires a plan or insurer to directly reimburse a nonparticipating essential community provider the greater of its average contracted rate or 125% of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (KKA), the California Department of Insurance (CDI) to regulate health insurance. [HSC §1340, et seq. and INS §106, et seq.]
- Requires a group or individual nongrandfathered health plan contract or health insurance policy, at a minimum, to provide coverage for and not impose any cost-sharing requirements for any of the following (This is referred to as the preventive services mandate):
- Evidence-based items or services that have in effect a rating of “A” or “B” in the recommendations of the United States Preventive Services Task Force (USPSTF), as periodically updated. Indicates the current recommendations of the USPSTF regarding breast cancer screening, mammography, and prevention is considered the most current other than those issued in or around November 2009;
- Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the CDC with respect to the individual involved;
- With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the U.S. Health Resources and Services Administration (HRSA); and,
- With respect to women, those additional preventive care and screenings as provided for in comprehensive guidelines supported by HRSA. [HSC §1367.002 and INS §10112.2]
- Prohibits a plan or insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis (PrEP) or postexposure prophylaxis (PEP) to prior authorization or step therapy. However, if one or more therapeutic equivalents has been approved by the U.S. Food and Drug Administrating (FDA) at least one must be covered without prior authorization or step therapy. [HSC §1342.74 and INS §10123.1933]
- Requires every health plan contract and health insurance policy to provide coverage for home test kits for sexually transmitted infections (STIs), including laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered by an in-network clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs. [HSC §1367.34 and INS §10123.208]
- Requires every health plan contract and every health insurance policy, except a specialized health plan contract or specialized insurance policy, to provide coverage without any cost-sharing for a colorectal cancer screening test assigned either a grade A or a grade of B by the USPSTF, and the required colonoscopy following a positive test or procedure. [HSC §1367.668 and INS §10123.207]
- Requires a health plan contract and individual or group policy of disability insurance, except a specialized health plan contract or specialized insurance policy, to cover all FDA-approved contraceptive drugs, devices, and other products, including all FDA-approved contraceptive drugs, devices, and products available over the counter, as prescribed by the enrollee’s provider. Requires, beginning on or after January 1, 2024, coverage without a prescription and point-of-sale coverage without cost-sharing or medical management of over-the-counter FDA-approved contraceptive drugs, devices, and products at in-network pharmacies. [Section §1367.25 and INS §10123.196]
This bill:
- Prohibits a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by the preventive services mandate, or, for any items or services that are integral to the provision of an item or service that is required by the preventive services mandate, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by the preventive services mandate.
- Requires a health plan or health insurer to provide coverage for modified or upgraded recommendations or guidelines no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
- Prohibits a large group health plan contract or insurance policy issued, amended, or renewed on or after January 1, 2024, and an individual or small group health plan contract or insurance policy issued, amended or renewed on or after January 1, 2025, from imposing a cost-sharing requirement on a STI screening that is recommended by the CDC in the most recently updated version of its STI Treatment Guidelines, or as most recently recommended by the CDC in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the USPSTF conflicts with that of the CDC, or omits a CDC screening recommendation, prohibits a health plan contract or health insurance policy from requiring any cost-sharing for a STI screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDC’s recommendation.
- Prohibits a health plan contract or health insurance policy, notwithstanding federal law, issued, amended, or renewed on or after January 1, 2024, from requiring or imposing prior authorization or other limits, as specified, for coverage of STI screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory.
- Prohibits a large health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, and an individual and small group health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2025from imposing a cost-sharing requirement for STI, or for any items and services that are integral to a screening, under this bill, or existing law, as specified, regardless of any of the following:
- The location of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting;
- The screening test, testing method or algorithm, or method of sample collection or processing;
- The identity or qualifications of the individual who collected or processed a sample; and,
- The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
- Requires a health plan or health insurer to directly reimburse a nonparticipating provider or facility of STI screening for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. Requires, for items and services rendered subject to this bill, unless otherwise agreed to by a nonparticipating essential community provider and the health plan or health insurer, the plan or insurer to reimburse an essential community provider the greater of its average contracted rate or 125% of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered.
- Prohibits the delayed implementation with respect to individual and small group health plan contracts and health insurance policies from excusing a plan or insurer from compliance with specified law.
Comments
- STI Screening. California Health Benefits Review Program (CHBRP) indicates recommendations vary as to which groups of persons should be screened and as to how often screenings should occur but STI screening is commonly recommended for the following:
- Chlamydia
- Gonorrhea
- Syphilis
- Hepatitis B and C
- HIV
- Human papillomavirus (HPV)
The addition of the CDC recommendations to the USPSTF recommendations would expand the risk groups covered for the following STIs:
- Screening for chlamydia and gonorrhea for men who have sex with men (MSM), MSM on PrEP, with HIV infection, or with multiple partners (every three to six months); transgender and gender diverse: consider screening at rectal site based on behaviors and exposure.
- Screening for syphilis for transgender and gender diverse people at least annually.
- Screening for hepatitis B for women with more than one sex partner in the previous six months.
- Annual screening for hepatitis C for MSM with HIV infection.
- HIV screening for transgender persons.
- Digital anorectal screening for HPV for MSM.
- CHBRP report. Key findings include:
- Coverage impacts and enrollees covered. 0% of commercial/CalPERS enrollees have benefit coverage fully compliant with the STI and cost-sharing requirements of this bill and only 18% have insurance that is fully compliant with requirements to see an out-of-network provider without prior authorization. 99% of commercial/CalPERS enrollees in nongrandfathered plans or policies have coverage fully compliant with this bill’s expanded preventive services requirements.
- Medical effectiveness. Based on the recommendations from the four entities referenced by the California Preventive Services mandates, as well as recommendations from the CDC, CHBRP considers all of the recommended preventive services and STI screenings to have clear and convincing evidence of medical effectiveness. Although CHBRP found insufficient evidence that the prohibition of cost-sharing would substantially impact utilization, this conclusion is based on a generalized summary across a variety of preventive services.
- Utilization. CHBRP estimates 25% of all STI testing and treatment is done on a self-pay basis among insured enrollees at baseline and postmandate due to privacy preferences. Thus, 75% are purchased with insurance, and only this subset will experience changes due to removal of cost-sharing and prior authorization. However, this is an overall estimate and varies across the following categories. This bill does not significantly change the proportion of individuals who choose to remain anonymous regarding STI screening and thus do not use insurance benefits to obtain STI screening.
- Impact on expenditures. CHBRP estimates that premiums for employers, employees, individuals and families will increase by $24,973,000 because of this bill and cost-sharing for STI treatments would increase by $2,751,000. Enrollee expenses for noncovered benefits would decrease by $7,659,000.
Related/Prior Legislation
SB 523 (Leyva, Chapter 630, Statutes of 2022) required coverage for FDA-approved contraceptive drugs, devices, and products without cost-sharing and medical management applicable to all insureds and enrollees, as specified, and required employee health benefit plan contracts provided by the CalPERS, the University of California, the California State University, and plans directly operated by a bona fide public or private institution of higher learning to comply.
SB 306 (Pan, Chapter 486, Statutes of 2021) permitted pharmacists to dispense a drug, without the name of an individual for whom the drug is intended, when prescribed for the sexual partner of someone who has been diagnosed with a STD; prohibited health care providers who prescribe, dispense, or furnish such a drug from being subject to, civil, criminal, or administrative penalties, as specified; required a syphilis blood test, during the third trimester of pregnancy and at delivery, as specified; requires public and commercial health coverage of home STD test kits; and added rapid STD tests to existing law which permits HIV counselors to perform rapid HIV and hepatitis C tests.
AB 342 (Gipson, Chapter 436, Statutes of 2021) required a health plan contract or a health insurance policy, except as specified, to provide coverage for a colorectal cancer screening test, and requires a colonoscopy for a positive result on a test or procedure to be provided without cost-sharing, unless the underlying test or procedure was a colonoscopy.
SB 159 (Wiener, Chapter 532, Statutes of 2019) authorized a pharmacist to initiate and furnish HIV PrEP and PEP, as specified.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee:
- DMHC estimates costs of approximately $707,000 in 2023-24, $1,607,000 in 2024-25, and $1,619,000 in 2025-26 and annually thereafter for state administration (Managed Care Fund).
- CDI anticipates no fiscal impact.
- Unknown General Fund costs due to increased CalPERS health plan premiums.
SUPPORT: (Verified 9/1/23)
Insurance Commissioner Ricardo Lara (co-source)
APLA Health (co-source)
Equality California (co-source)
Los Angeles LGBT Center (co-source)
San Francisco AIDS Foundation (co-source)
AIDS Healthcare Foundation
Asian Liver Center at Stanford University
Bienestar Human Services
California Hepatitis Alliance
California LGBTQ Health and Human Services Network
California Life Sciences
California School-Based Health Alliance
California Transcends
Citizens for Choice
City of Long Beach
Color Health, Inc.
Community Clinic Association of Los Angeles County
County of Los Angeles Board of Supervisors
End Hep C San Francisco
End the Epidemics
Essential Access Health
Gender Spectrum
GLIDE
Health Access California
Hep B Free - San Francisco Bay Area
Justice in Aging
Lyon-Martin Community Health
National Health Law Program
Planned Parenthood Affiliates of California
Positive Images LGBTQIA+ Center
Radiant Health Centers
San Diego Pride
Somos Familia Valle
Source LGBT+ Center
The Women's Building
TransYouth Liberation
Venice Family Clinic
Viet Rainbow of Orange County
Western Center on Law & Poverty, Inc.
OPPOSITION: (Verified 9/1/23)
America's Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
California Chamber of Commerce
Department of Finance
ARGUMENTS IN SUPPORT: Commissioner Lara, a co-sponsor of this bill, writes that current California law relating to preventive health care and screenings for STIs contains loopholes that need closing. Current guidance prohibits cost-sharing on screenings that are recommended by the USPSTF but does not always align with current best clinical practices in STI screening. Because the current requirement for STI screening without cost-sharing is connected to recommendations from the USPSTF, rather than guidelines from the CDC, patients may be responsible for costs associated with STI screening that is recommended by the CDC. While California law will continue requiring state-regulated health plans to cover preventive services without cost-sharing, there are loopholes that need closing. This bill will strengthen existing law in the face of these incessant judicial attacks on the ACA and ensure that health plans cover the full spectrum of preventive services without cost-sharing, including office visits and other necessary health care services for delivering a preventive benefit.
ARGUMENTS IN OPPOSITION: The California Chamber of Commerce writes that when looking at health care cost increases in isolation they seem tolerable, however, this bill must be considered in context. Premiums for employers and enrollees consistently increase year after year due to a number of issues including benefit mandates.
The California Association of Health Plans, the Association of California Life & Health Insurance Companies, and America’s Health Insurance Plans write in opposition to this along with other health insurance mandate bills. These bills include mandates for health plans and insurers to cover specific services, as well as bills that eliminate cost-sharing and limit utilization management, which have similar cost impacts as coverage mandates. According to these organizations, if taken together, these bills will increase premiums by at least $742,533,000 in 2024 alone, with projected additional increases in out years. Benefit mandates that do not promote evidence-based medicine can lead to lower quality care, over- or misutilization of services, and higher costs for treatments that may be ineffective, less safe, or higher cost than other, new or trusted services.
The Department of Finance is opposed to this bill, arguing that it creates ongoing costs and pressures to the General Fund and Managed Care Fund, resulting from increased administrative costs for implementation and state-funded healthcare premiums. Additionally, the preventive services required under this bill exceeds the federal Affordable Care Act. To the extent this bill results in additional assessments on health plans and insurers, consumers may face increased health care premiums.
ASSEMBLY FLOOR: 64-10, 5/31/23
AYES: Addis, Aguiar-Curry, Alvarez, Arambula, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Juan Carrillo, Wendy Carrillo, Cervantes, Connolly, Mike Fong, Friedman, Gabriel, Garcia, Gipson, Grayson, Haney, Hart, Holden, Irwin, Jackson, Jones-Sawyer, Kalra, Lee, Low, Lowenthal, Maienschein, McCarty, McKinnor, Muratsuchi, Stephanie Nguyen, Ortega, Pacheco, Papan, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Santiago, Schiavo, Soria, Ting, Valencia, Villapudua, Waldron, Wallis, Ward, Weber, Wicks, Wilson, Wood, Zbur, Rendon
NOES: Alanis, Megan Dahle, Davies, Dixon, Essayli, Flora, Gallagher, Hoover, Jim Patterson, Ta
NO VOTE RECORDED: Chen, Vince Fong, Lackey, Mathis, Joe Patterson, Sanchez
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
9/4/23 9:47:04
**** END ****
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anthony Portantino, Chair
2023 - 2024 Regular Session
AB 1645 (Zbur) - Health care coverage: cost sharing
Version: July 13, 2023 | Policy Vote: HEALTH 10 - 1 |
Urgency: No | Mandate: Yes |
Hearing Date: August 14, 2023 | Consultant: Agnes Lee |
Bill Summary:
AB 1645 would expand health insurance coverage for preventive services without cost-sharing to include office visits and services integral to the provision of those services, as defined; and would prohibit cost-sharing and limitations on sexually transmitted infections (STI) screenings and services integral to an STI screening, as specified.
Fiscal Impact:
- The Department of Managed Health Care (DMHC) estimates costs of approximately $707,000 in 2023-24, $1,607,000 in 2024-25, and $1,619,000 in 2025-26 and annually thereafter for state administration (Managed Care Fund).
- The California Department of Insurance (CDI) anticipates no fiscal impact.
- Unknown General Fund costs due to increased CalPERS health plan premiums.
Background:
The DMHC regulates health plans under the Knox-Keene Act and the CDI regulates health insurance. Current law requires a group or individual nongrandfathered health plan contract or health insurance policy, at a minimum, to provide coverage for and not impose any cost-sharing requirements for any of the following (this is referred to as the preventive services mandate):
- Evidence-based items or services that have in effect a rating of “A” or “B” in the recommendations of the United States Preventive Services Task Force (USPSTF), as periodically updated;
- Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention (CDC) with respect to the individual involved;
- With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the U.S. Health Resources and Services Administration (HRSA); and,
- With respect to women, those additional preventive care and screenings as provided for in comprehensive guidelines supported by HRSA.
Proposed Law:
Specific provisions of the bill would:
- Prohibit a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by the preventive services mandate, or for any items or services that are integral to the provision of an item or service that is required by the preventive services mandate, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by the preventive services mandate.
- Define “integral item or service.”
- Prohibit a large group health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, or an individual or small group contract or policy issued, amended, or renewed on or after January 1, 2025, from imposing a cost-sharing requirement on an STI screening or for items and services that are integral to a screening, as specified.
- Prohibit a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from requiring or imposing any of the following for coverage of STI screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
- Prior authorization or other utilization review requirements.
- Limits on frequency, method, treatment, or setting.
- Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
- Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
- Other limits, as specified.
- Require a health plan or health insurer to directly reimburse a nonparticipating provider or facility of STI screening for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered; and would prohibit a nonparticipating essential community provider from billing or collecting any cost-sharing amounts from an enrollee or insured for an STI screening, or for integral items and services.
Staff Comments: The California Health Benefits Review Program (CHBRP) analysis of AB 1645, as introduced, estimates an increase in total net annual expenditures of $20,065,000 for enrollees with DMHC-regulated plans and CDI-regulated policies. This includes an increase of $3.1 million for CalPERS health plan premiums. The CHBRP analysis indicates no fiscal impact to the Medi-Cal program.
-- END --
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anthony Portantino, Chair
2023 - 2024 Regular Session
AB 1645 (Zbur) - Health care coverage: cost sharing
Version: July 13, 2023 | Policy Vote: HEALTH 10 - 1 |
Urgency: No | Mandate: Yes |
Hearing Date: August 14, 2023 | Consultant: Agnes Lee |
Bill Summary:
AB 1645 would expand health insurance coverage for preventive services without cost-sharing to include office visits and services integral to the provision of those services, as defined; and would prohibit cost-sharing and limitations on sexually transmitted infections (STI) screenings and services integral to an STI screening, as specified.
Fiscal Impact:
- The Department of Managed Health Care (DMHC) estimates costs of approximately $707,000 in 2023-24, $1,607,000 in 2024-25, and $1,619,000 in 2025-26 and annually thereafter for state administration (Managed Care Fund).
- The California Department of Insurance (CDI) anticipates no fiscal impact.
- Unknown General Fund costs due to increased CalPERS health plan premiums.
Background:
The DMHC regulates health plans under the Knox-Keene Act and the CDI regulates health insurance. Current law requires a group or individual nongrandfathered health plan contract or health insurance policy, at a minimum, to provide coverage for and not impose any cost-sharing requirements for any of the following (this is referred to as the preventive services mandate):
- Evidence-based items or services that have in effect a rating of “A” or “B” in the recommendations of the United States Preventive Services Task Force (USPSTF), as periodically updated;
- Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention (CDC) with respect to the individual involved;
- With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the U.S. Health Resources and Services Administration (HRSA); and,
- With respect to women, those additional preventive care and screenings as provided for in comprehensive guidelines supported by HRSA.
Proposed Law:
Specific provisions of the bill would:
- Prohibit a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by the preventive services mandate, or for any items or services that are integral to the provision of an item or service that is required by the preventive services mandate, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by the preventive services mandate.
- Define “integral item or service.”
- Prohibit a large group health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, or an individual or small group contract or policy issued, amended, or renewed on or after January 1, 2025, from imposing a cost-sharing requirement on an STI screening or for items and services that are integral to a screening, as specified.
- Prohibit a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from requiring or imposing any of the following for coverage of STI screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
- Prior authorization or other utilization review requirements.
- Limits on frequency, method, treatment, or setting.
- Limits on confirmatory or post-treatment retesting of an asymptomatic patient.
- Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening.
- Other limits, as specified.
- Require a health plan or health insurer to directly reimburse a nonparticipating provider or facility of STI screening for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered; and would prohibit a nonparticipating essential community provider from billing or collecting any cost-sharing amounts from an enrollee or insured for an STI screening, or for integral items and services.
Staff Comments: The California Health Benefits Review Program (CHBRP) analysis of AB 1645, as introduced, estimates an increase in total net annual expenditures of $20,065,000 for enrollees with DMHC-regulated plans and CDI-regulated policies. This includes an increase of $3.1 million for CalPERS health plan premiums. The CHBRP analysis indicates no fiscal impact to the Medi-Cal program.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Susan Talamantes Eggman, Chair
BILL NO: AB 1645
AUTHOR: | Zbur | ||
VERSION: | July 3, 2023 | ||
HEARING DATE: | July 12, 2023 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Health care coverage: cost-sharing
SUMMARY:
Expands health insurance coverage for preventive services without cost-sharing to include office visits and services integral to the provision of the item or service, and requires coverage earlier than federal requirements. Prohibits a group or individual health plan contract or insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement or prior authorization on a sexually transmitted infection screening that is recommended by the federal Centers for Disease Control and Prevention or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory, and requires a plan or insurer to directly reimburse a nonparticipating essential community provider the greater of its average contracted rate or 125% of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (KKA), the California Department of Insurance (CDI) to regulate health insurance. [HSC §1340, et seq. and INS §106, et seq.]
- Requires a group or individual nongrandfathered health plan contract or health insurance policy, at a minimum, to provide coverage for and not impose any cost-sharing requirements for any of the following (This is referred to as the preventive services mandate):
- Evidence-based items or services that have in effect a rating of “A” or “B” in the recommendations of the United States Preventive Services Task Force (USPSTF), as periodically updated. Indicates the current recommendations of the USPSTF regarding breast cancer screening, mammography, and prevention is considered the most current other than those issued in or around November 2009;
- Immunizations that have in effect a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention (CDC) with respect to the individual involved;
- With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines, as periodically updated, supported by the U.S. Health Resources and Services Administration (HRSA); and,
- With respect to women, those additional preventive care and screenings as provided for in comprehensive guidelines supported by HRSA. [HSC §1367.002 and INS §10112.2]
- Prohibits a plan or insurer from subjecting antiretroviral drugs that are medically necessary for the prevention of AIDS/HIV, including preexposure prophylaxis (PrEP) or postexposure prophylaxisand (PEP) to prior authorization or step therapy. However, if one or more therapeutic equivalents has been approved by the U.S. Food and Drug Administrating (FDA) at least one must be covered without prior authorization or step therapy. [HSC §1342.74 and INS §10123.1933]
- Requires every health plan contract and health insurance policy to provide coverage for home test kits for sexually transmitted infections (STIs), including laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered by an in-network clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs. [HSC §1367.34 and INS §10123.208]
- Requires every health plan contract and every health insurance policy, except a specialized health plan contract or specialized insurance policy, to provide coverage without any cost-sharing for a colorectal cancer screening test assigned either a grade A or a grade of B by the USPSTF, and the required colonoscopy following a positive test or procedure. [HSC §1367.668 and INS §10123.207]
- Requires a health plan contract and individual or group policy of disability insurance, except a specialized health plan contract or specialized insurance policy, to cover all FDA-approved contraceptive drugs, devices, and other products, including all FDA-approved contraceptive drugs, devices, and products available over the counter, as prescribed by the enrollee’s provider. Requires, beginning on or after January 1, 2024, coverage without a prescription and point-of-sale coverage without cost-sharing or medical management of over-the-counter FDA-approved contraceptive drugs, devices, and products at in-network pharmacies. [Section §1367.25 and INS §10123.196]
This bill:
- Prohibits a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing any cost-sharing requirement for office visits that are associated with the provision of an item or service that is required by the preventive services mandate, or, for any items or services that are integral to the provision of an item or service that is required by the preventive services mandate, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service that is required by the preventive services mandate.
- Establishes the following definitions:
- “Integral item or service” as an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by the preventive services mandate; and,
- “Current, generally accepted standard of care or clinical practice” means standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the CDC, and product labeling approved by the FDA.
- Requires a health plan or health insurer to provide coverage for modified or upgraded recommendations or guidelines no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
- Requires a health plan contract or health insurance policy to cover items and services in accordance with an applicable requirements of the KKA and Insurance Code, including, but not limited to requirements on prophylaxis of HIV infection, STIs screening, home test kits for STIs, and on colorectal cancer screening, as specified.
- Indicates, notwithstanding, that specified existing law exclusively governs the coverage of contraceptive drugs, devices, and products.
- Prohibits a group or individual health plan contract or insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement on a STI screening that is recommended by the CDC in the most recently updated version of its STI Treatment Guidelines, or as most recently recommended by the CDC in the Morbidity and Mortality Weekly Report or similar method of official public communication. If a screening recommendation of the USPSTF conflicts with that of the CDC, or omits a CDC screening recommendation, prohibits a health plan contract or health insurance policy from requiring any cost-sharing for a STI screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDC’s recommendation.
- Prohibits a health plan contract or health insurance policy, notwithstanding federal law, issued, amended, or renewed on or after January 1, 2024, from requiring or imposing any of the following for coverage of STI screening, or of any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory:
- Prior authorization or other utilization review requirements;
- Limits on frequency, method, treatment, or setting;
- Limits on confirmatory or post-treatment retesting of an asymptomatic patient;
- Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening; and,
- Any other limits on the coverage or provision of STI screening as a preventive item or service under this bill or existing law, as specified, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice as prohibited by the KKA or Insurance Code.
- Prohibits a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement for STI, or for any items and services that are integral to a screening, under this bill, or existing law, as specified, regardless of any of the following:
- The location of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting;
- The screening test, testing method or algorithm, or method of sample collection or processing;
- The identity or qualifications of the individual who collected or processed a sample; and,
- The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
- Requires a health plan or health insurer to directly reimburse a nonparticipating provider or facility of STI screening for screening tests and integral items and services rendered, if the provider or facility was an essential community provider when the screening tests and integral items and services were rendered. Requires if a nonparticipating essential community provider does not generate the results of screening, the provider to submit the samples to a participating processing laboratory. Prohibits a nonparticipating essential community provider from billing or collecting any cost-sharing amounts from an enrollee or insured for a STI screening, or for integral items and services, under this bill, and existing law. Requires, for items and services rendered subject to this bill, unless otherwise agreed to by a nonparticipating essential community provider and the health plan or health insurer, the plan or insurer to reimburse an essential community provider the greater of its average contracted rate or 125% of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered.
- Establishes, for 9) above, the following definitions:
- “Average contracted rate” means the average of the contracted commercial rates paid by the health plan or insurer for the same or similar items or services in the geographic region.
- “Essential community provider” means a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchange’s Essential Community Provider List.
FISCAL EFFECT:
According to the Assembly Appropriations Committee:
- No costs to CDI.
- DMHC estimates the total cost of this bill to be approximately $707,000 in fiscal year (FY) 2023-24 and $1.6 million in FY 2024-25 and annually thereafter.
- California Health Benefits Review Program (CHBRP) estimates this bill will have no effect on costs to Medi-Cal.
- CHBRP estimates increases in CalPERS premiums of $3.1 million (0.05%); a substantial but unknown portion of these premiums is paid by the state (General Fund, special funds).
- CHBRP estimates this bill will increase total net annual expenditures by $20,065,000, or 0.01%, for DMHC-regulated plans and CDI-regulated policies. The increase in total health insurance premiums paid by employers and enrollees for newly covered benefits includes a reduction in enrollee expenditures of $7.7 million (1.84%) as a result of this bill.
PRIOR VOTES:
Assembly Floor: | 64 - 10 |
Assembly Appropriations Committee: | 11 - 2 |
Assembly Health Committee: | 12 - 0 |
COMMENTS:
- Author’s statement. According to the author, every Californian deserves access to preventive health care that is comprehensive, inclusive, and affordable. Current California law relating to preventive health care and screenings for STI contains loopholes that need closing. This bill ensures that patients can access not only preventive care but also all of the services and office visits that are necessary for delivering that care without cost-sharing, including medication management and lab testing for PrEP, a life-saving HIV prevention medication.
- STI Screening. CHBRP indicates recommendations vary as to which groups of persons should be screened and as to how often screenings should occur but STI screening is commonly recommended for the following:
- Chlamydia
- Gonorrhea
- Syphilis
- Hepatitis B and C
- HIV
- Human papillomavirus (HPV)
The addition of the CDC recommendations to the USPSTF recommendations would expand the risk groups covered for the following STIs:
- Screening for chlamydia and gonorrhea for men who have sex with men (MSM), MSM on PrEP, with HIV infection, or with multiple partners (every three to six months); transgender and gender diverse: consider screening at rectal site based on behaviors and exposure.
- Screening for syphilis for transgender and gender diverse people at least annually.
- Screening for hepatitis B for women with more than one sex partner in the previous six months.
- Annual screening for hepatitis C for MSM with HIV infection.
- HIV screening for transgender persons.
- Digital anorectal screening for HPV for MSM.
- CHBRP report. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill. Key findings include:
- Assumptions.
- CHBRP assumes that the availability of out-of-network services would increase out-of-network utilization of STI screenings and associated services by 3.0% for impacted populations without current out-of-network benefits. CHBRP further assumes that this 3.0% would be split as 50% from baseline in-network services and 50% new utilization.
- CHBRP assumes that the availability of Community Essential Providers would increase utilization of STI screenings and associated services by 3% for impacted populations without current out-of-network benefits. CHBRP further assumes that this 3.0% would be split as 50% from baseline in-network services and 50% new utilization.
- CHBRP assumes that this bill would result in a shift of 0.6% from self-pay STI screening to out-of-network STI screenings.
- CHBRP assumes that this bill would increase utilization of STI screenings among qualifying enrollees of grandfathered plans by 25% due to cost-sharing prohibition. The total impact of this assumption on STI screening utilization across all populations is approximately 0.8%.
- Coverage impacts and enrollees covered. 0% of commercial/CalPERS enrollees have benefit coverage fully compliant with the STI and cost-sharing requirements of this bill and only 18% have insurance that is fully compliant with requirements to see an out-of-network provider without prior authorization. 99% of commercial/CalPERS enrollees in nongrandfathered plans or policies have coverage fully compliant with this bill’s expanded preventive services requirements.
- Medical effectiveness. Based on the recommendations from the four entities referenced by the California Preventive Services mandates – as well as recommendations from the CDC– CHBRP considers all of the recommended preventive services and STI screenings to have clear and convincing evidence of medical effectiveness. Although CHBRP found insufficient evidence that the prohibition of cost-sharing would substantially impact utilization, this conclusion is based on a generalized summary across a variety of preventive services. The body of literature on this topic is of a widely varied nature with regard to both the preventive services of focus, and the quality of the research. The findings also differ considerably with regard to the specific preventive services with some finding more consistent utilization increases than others.
- Utilization.
- STI. CHBRP estimates 25% of all STI testing and treatment is done on a self-pay basis among insured enrollees at baseline and postmandate due to privacy preferences. Thus, 75% are purchased with insurance, and only this subset will experience changes due to removal of cost-sharing and prior authorization. However, this is an overall estimate and varies across the following categories. Each is explained below:
- CHBRP estimates that home test kits are used for approximately 10% of all STI tests. CHBRP also estimates that home tests kits are disproportionately preferred by individuals who wish to remain anonymous, such that, among commercial/CalPERS enrollees, 75% of home test kits are purchased by enrollees without using insurance benefits. Thus, 25% of home test kits are purchased using insurance benefits. Given this estimate regarding the proportion of enrollees who prefer testing anonymity, the removal of cost-sharing and prior authorization will only impact the baseline 25% of home kits purchased with insurance, increasing utilization by 2.7%.
- Among commercial/CalPERS enrollees, utilization management testing limits for STI screening from in-network providers occurs for <1% of enrollees. Thus, the postmandate impact is the combined effect of the removal of cost-sharing and removal of these testing limits, where the relevant expansion of risk groups is based on the most recent CDC STI screening recommendations, and where the size of each risk group in California is based on estimates from the California
Health Interview Survey. - In addition, CHBRP estimates 3% of in-network covered screening will move to out of network covered screening. This will result in a net increase in utilization of 0.52%.
- Approximately 82% of commercial/CalPERS enrollees are subject to prior authorization before STI screening by an out-of-network is covered (in other words, 18% of enrollees have benefits that do not require prior authorization). The removal of prior authorization and frequency limits combined with the removal of cost-sharing will result in an increase of covered STI screening through out-of-network providers increasing by 22%. This bill will not significantly change the proportion of individuals who choose to remain anonymous regarding
STI screening and thus do not use insurance benefits to obtain STI screening. Enrollees making this choice are likely to use essential community providers. However, these enrollees are largely unlikely to use the expanded coverage mandated by this bill, as doing so would remove their anonymity. The primary purpose of STI screening is to identify and treat new STI cases, which both helps the infected person and decreases the spread of the disease. Evidence suggests that not all who test positive for STIs go on to get treatment. CHBRP has assumed an increase in STI screening due to this bill would increase treatment for HIV, hepatitis C, and all other STIs. For HIV and hepatitis C, due to the lower prevalence of disease, treatment is not expected to increase to the same degree as for other STIs. Given the wider spread of HIV testing programs, the likelihood of finding a new positive due to increased testing due to this bill is smaller than that for hepatitis C, which is not
as widely tested.
- Other preventive services. Use of other preventive services by commercial/CalPERS enrollees is expected to increase by 0.06%. There are too many integral services to list, but examples include administration of the flu vaccine; administration of, and associated lab tests that precede, a colonoscopy; etc.
- STI. CHBRP estimates 25% of all STI testing and treatment is done on a self-pay basis among insured enrollees at baseline and postmandate due to privacy preferences. Thus, 75% are purchased with insurance, and only this subset will experience changes due to removal of cost-sharing and prior authorization. However, this is an overall estimate and varies across the following categories. Each is explained below:
- Medi-Cal. This bill does not impact Medi-Cal enrollees as it only applies to individual and group health insurance coverage.
- Impact on expenditures. CHBRP estimates that premiums for employers, employees, individuals and families will increase by $24,973,000 because of this bill and cost-sharing for STI treatments would increase by $2,751,000. Enrollee expenses for noncovered benefits would decrease by $7,659,000.
- Public health. In the first year postmandate, CHBRP estimates an additional 116,300 tests will be conducted to screen for STIs and that an additional 93,000 treatments for STIs including HIV will be delivered. As there is clear and convincing evidence that there are STI screening and treatments that are medically effective at identifying and
treating STIs, disease transmission is expected to decline, leading to improved health outcomes. In the first-year post-mandate, CHBRP estimates an additional approximately 15,704 other preventive services will be provided. There is clear and convincing evidence that there are preventive services that are medically effective at improving health and preventing disease. Therefore, it is estimated that health outcomes will improve overall as a result of this bill. - Essential health benefits. This bill would not require coverage for a new state benefit mandate and appears not to exceed the definition of EHBs.
- Assumptions.
- Essential community providers. Covered California, California’s Affordable Care Act (ACA) health benefit exchange, requires plans to include essential community providers in their qualified health plan networks. An essential community provider is a provider who serves low-income and medically underserved communities. There are many thousands of providers on Covered California’s essential community provider list. Categories of these essential community providers include:
- 340B entities (clinics, hospitals and other entities);
- California Disproportionate Share Hospitals, defined by DHCS;
- Federally Qualified Health Centers;
- Federally designated 638 Tribal Health Programs and Title V Urban Indian Health Organizations;
- Providers licensed as "community clinic" or "free clinic”, or is a community or free clinic exempt from licensure; and,
- Providers who qualified for HI-TECH Medi-Cal Electronic Health Record Incentive Program dollars. These are eligible providers who completed the application process for this federal program, administered by the DHCS, to distribute financial resources to encourage providers to establish electronic medical records.
- Related legislation. SB 339 (Weiner) requires health plans and health insurers to cover PrEP and PEP furnished by a pharmacist, including costs for the pharmacist’s services and related testing ordered by the pharmacist, and to reimburse pharmacist services at 100% of the fee schedule for physician services. SB 339 includes PrEP furnished by a pharmacist as pharmacist services on the Medi-Cal schedule of benefits. SB 339 authorizes a pharmacist to furnish up to a 90 day course of PrEP, or beyond a 90 day course (existing law allows for a 60 day supply), if specified conditions are met. SB 339 is set to be heard in the Assembly Business and Professions Committee on July 11, 2023.
SB 427 (Portantino) prohibits nongrandfathered health plans and insurers from imposing any cost-sharing or utilization review requirements for antiretroviral drugs, devices, or products that are either FDA-approved or recommended by the CDC for the prevention of AIDS/HIV. SB 427 requires grandfathered health plans and insurers to provide coverage, without any cost-sharing or utilization review requirements, for antiretroviral drugs, devices, or products that are either jFDA-approved or recommended by the CDC for the prevention of AIDS/HIV. SB 427 is set to be heard in the Assembly Committee on Health on July 11, 2023.
SB 541 (Menjivar) requires schools to make internal and external condoms available for free to all students in grades nine through 12. SB 541 also requires the Family Planning Access Care Treatment (PACT) program to provide coverage for HPV immunization for persons between 12 and 18 years of age. SB 541 is set to be heard in the Assembly Committee on Health on July 11, 2023.
- Prior legislation. SB 523 (Leyva, Chapter 630, Statutes of 2022) requires coverage for FDA-approved contraceptive drugs, devices, and products without cost-sharing and medical management applicable to all insureds and enrollees, as specified, and requires employee health benefit plan contracts provided by the CalPERS, the University of California, the California State University, and plans directly operated by a bona fide public or private institution of higher learning to comply.
SB 306 (Pan, Chapter 486, Statutes of 2021), permits pharmacists to dispense a drug, without the name of an individual for whom the drug is intended, when prescribed for the sexual partner of someone who has been diagnosed with a STD; prohibits health care providers who prescribe, dispense, or furnish such a drug from being subject to, civil, criminal, or administrative penalties, as specified; requires a syphilis blood test, during the third trimester of pregnancy and at delivery, as specified; requires public and commercial health coverage of home STD test kits; and adds rapid STD tests to existing law which permits HIV counselors to perform rapid HIV and hepatitis C tests.
AB 342 (Gipson, Chapter 436, Statutes of 2021), requires a health plan contract or a health insurance policy, except as specified, to provide coverage for a colorectal cancer screening test, and requires a colonoscopy for a positive result on a test or procedure to be provided without cost-sharing, unless the underlying test or procedure was a colonoscopy.
SB 159 (Wiener, Chapter 532, Statutes of 2019), authorizes a pharmacist to initiate and furnish HIV PrEP and PEP, as specified.
- Support. Commissioner Lara, (a cosponsor of this bill) writes current California law relating to preventive health care and screenings for STIs contains loopholes that need closing. Current guidance prohibits cost-sharing on screenings that are recommended by the USPSTF but does not always align with current best clinical practices in STI screening. Because the current requirement for STI screening without cost-sharing is connected to recommendations from the USPSTF, rather than guidelines from the CDC, patients may be responsible for costs associated with STI screening that is recommended by the CDC. For example, the USPSTF does not recommend screening MSM or persons with HIV for chlamydia and gonorrhea, contrary to the CDC. Additionally, while the CDC recommends routine periodic screening of persons with ongoing risk factors for hepatitis C virus, including persons who inject drugs or who are living with HIV, the USPSTF provides far less guidance on screening of high-risk populations. Under the USPSTF’s screening recommendation, a person who is under age 18 is ineligible for Hepatitis C screening regardless of increased risk, despite almost half of STIs being among adolescents and young adults ages 15 to 24. These disparities between the USPSTF’s screening recommendations and those of the CDC disproportionately burden our youth, LGBTQ+ people, and communities of color, who are affected by STIs at a higher rate than other demographic groups. Other proponents and cosponsors write that on March 30, 2023, a U.S. District Court Judge struck down national protections for critical preventive care benefits under the federal ACA. While California law will continue requiring state-regulated health plans to cover preventive services without cost-sharing, there are loopholes that need closing. This bill will strengthen existing law in the face of these incessant judicial attacks on the ACA and ensure that health plans cover the full spectrum of preventive services without cost-sharing, including office visits and other necessary health care services for delivering a preventive benefit.
- Opposition. The California Chamber of Commerce writes that when looking at health care cost increases in isolation they seem tolerable, however, this bill must be considered in context. Premiums for employers and enrollees consistently increase year after year due to a number of issues including benefit mandates. The 2022 Kaiser Family Foundation Employer Health Benefits Survey indicated that the average premium for family coverage has increased 20% over the last five years and 43% over the last 10 years. Additionally, annual premiums for employer-sponsored family health coverage reached $22,463 in 2022, with workers on average paying $6,106 toward the cost of their coverage. California must remain mindful when increasing the cost of health care coverage costs through legislation. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write in opposition to this along with 20 other health insurance mandate bills. These bills include mandates for health plans and insurers to cover specific services, as well as bills that eliminate cost-sharing and limit utilization management, which have similar cost impacts as coverage mandates. Taken together, these bills will increase premiums by at least $742,533,000 in 2024 alone, with projected additional increases in out years. Ultimately, these bills will harm affordability and access for small businesses and individual market consumers. Moreover, they will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. State mandates increase costs of coverage – especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates. Benefit mandates that do not promote evidence-based medicine can lead to lower quality care, over- or misutilization of services, and higher costs for treatments that may be ineffective, less safe, or higher cost than other, new or trusted services. California is rightly focused on achieving both universal coverage and cost containment at a time when the national conversation has shifted toward lower costs through less comprehensive options.
- Policy comment. There are tradeoffs that come with cost-sharing prohibitions with respect to certain bronze high deductible health plans and other plans offered through Covered California and their mirrored products available in the health insurance market outside of Covered California. Covered California notes that bills containing a cost-sharing mandate have to be assessed to determine impact on Covered California’s ability to set standard benefit designs that are compliant with federal and state actuarial value requirements. As such, when cost-sharing prohibitions become law and have an impact on actuarial value requirements it necessitates cost-sharing increases for other services. Covered California has requested a delay in the implementation of the provisions prohibiting cost-sharing for additional screenings for gonorrhea and chlamydia to 2025 in order to allow the cost-sharing prohibition to be built into their standard plan design.
- Amendments. In order to address Covered California’s concerns, this bill should be amended to delay implementation for contracts offered in the individual or small group market on or after January 1, 2025. There may also be typographical error in HSC 1367.002 (d)(1) and INS 10112.2 (d)(1) that needs correcting.
SUPPORT AND OPPOSITION:
Support: Insurance Commissioner Ricardo Lara (cosponsor)
Equality California (cosponsor)
APLA Health (cosponsor)
Los Angeles LGBT Center (cosponsor)
San Francisco AIDS Foundation (cosponsor)
AIDS Healthcare Foundation
Asian Liver Center At Stanford University
Bienestar Human Services
California Hepatitis Alliance
California LGBTQ Health and Human Services Network
California Life Sciences
California School-Based Health Alliance
California Transcends
Citizens for Choice
City of Long Beach
Color Health, Inc.
Community Clinic Association of Los Angeles County
County of Los Angeles Board of Supervisors
End Hep C San Francisco
End the Epidemics
Essential Access Health
Gender Spectrum
GLIDE
Health Access California
Hep B Free - San Francisco Bay Area
Justice in Aging
Lyon-Martin Community Health
National Health Law Program
Planned Parenthood Affiliates of California
Positive Images LGBTQIA+ Center
Radiant Health Centers
San Diego Pride
Somos Familia Valle
Source LGBT+ Center
The Women's Building
TransYouth Liberation
Venice Family Clinic
Viet Rainbow of Orange County
Western Center on Law & Poverty, INC.
Oppose: America's Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
California Chamber of Commerce
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1645
Author:(Zbur)
As Amended Ver:May 1, 2023
Majority vote
SUMMARY
Prohibits a group or individual health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement for office visits of specified preventive care services and screenings and for items or services that are integral to their provision. Prohibits health plan contracts and insurance policies from imposing a cost-sharing requirement, utilization review, or other specified limits on a recommended sexually transmitted infections (STI) screening, and from imposing a cost-sharing requirement for any items and services integral to a STI screening, as specified. Requires a health plan or insurer to directly reimburse specified nonparticipating providers or facilities of STI screening, specified rates (unless otherwise agreed to by a nonparticipating essential community provider (ECP) and the health plan or insurer, the greater of its average contracted rate or 125% of the amount Medicare reimburses on a fee-for-service basis for the same or similar items or services in the general geographic region in which the items or services were rendered) for screening tests and integral items and services rendered, and prohibits the nonparticipating provider from billing or collecting a cost-sharing amount for a STI screening from an enrollee or insured.
Major Provisions
COMMENTS
The California Health Benefits Review Program (CHBRP) writes that preventive services are services such as screening tests and counseling that aim to prevent illness and disease. Preventive services recommended are required to be covered without cost-sharing initially required by the federal Patient Protection and Affordable Care Act (ACA) and later codified in AB 306 (Pan), Chapter 486, Statutes of 2021. These requirements go into effect as soon as 12 months after a recommendation is issued. New recommendations or updated recommendations do appear periodically, as the sources consider changes in the health of the population and advances in science. This bill would add the Centers for Disease Control and Prevention (CDC) STI screening recommendations to this list of preventive services referenced in coverage mandates in California. This bill would not change the timing requirement for new recommendations but would require that coverage be compliant within 90 days of issue when an existing recommendation is modified or upgraded. CHBRP's analysis states that this bill amends California's preventive services mandate as follows:
- Under existing law:
- For commercial/CalPERS enrollees in nongrandfathered California Department of Insurance (CDI)-regulated policies and Department of Managed Health Care (DMHC)-regulated plans:
- Prohibits cost sharing for preventative items and services recommended by the ACA – beginning in the plan or policy year that follows publication of the recommendation.
- Allows a deductible for enrollees in health savings account (HSA) qualified high deductible health plan (HDHP) if not applying the deductible would disqualify the plan as a federally recognized HSA-HDHP.
- For commercial/CalPERS enrollees in nongrandfathered California Department of Insurance (CDI)-regulated policies and Department of Managed Health Care (DMHC)-regulated plans:
- This bill amends existing law to:
- Make compliance in no less than 90 days required for modified or upgraded preventive service recommendations (but not for new recommendations).
- Prohibit cost sharing for office visits and/or any item or service associated with provision of the referenced preventative items and services.
- Specify required compliance with existing California mandates that also address preventive services.
- This bill establishes a STI screening mandate to:
- For commercial/CalPERS enrollees in all CDI-regulated policies and DMHC-regulated plans grandfathered and nongrandfathered:
- Prohibits the application of cost sharing to coverage for STI screening – unless not applying the deductible for an enrollee in an HSA-HDHP would disqualify the plan as a federally recognized HSA-HDHP.
- Add the CDC STI screening recommendations to this list of preventive services referenced in coverage mandates in California and prohibit cost sharing for coverage for STI screenings or any related items or services, regardless of:
- The location or method of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting;
- The screening test, testing method or algorithm, or method of sample collection or processing;
- The identity or qualifications of the individual who collected or processed a sample; and,
- The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
- When accessed through an ECP listed on the Exchange's ECP, or when accessed through a participating provider, prohibit, for coverage of STI screenings and for any related items:
- Prior authorization or other utilization review requirements;
- Limits on frequency, method, treatment, or setting;
- Limits on confirmatory or post-treatment retesting of an asymptomatic patient;
- Limits based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening;
- Any other limits on the coverage or provision of STI screening as a preventive item or service under this section or other mandates related to STI screening, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this this bill.
- Requires that nonparticipating ECPs be reimbursed at the median contracted rate in the general geographic region
- For commercial/CalPERS enrollees in all CDI-regulated policies and DMHC-regulated plans grandfathered and nongrandfathered:
- CHBRP analysis. CHBRP states the following in its analysis of this bill:
- Enrollees covered. For STI screening, at baseline, 0% of the 14 million commercial/CalPERS enrollees have insurance that is fully compliant with the requirements of this bill with regard to cost sharing and only 18% have insurance that is fully compliant with the requirements of this bill with regard to being able to see a nonparticipating provider without prior authorization. Postmandate, all commercial/ CalPERS enrollees would have benefit coverage compliant with the STI screening mandate of this bill.
- Impact on expenditures. According to CHBRP, this bill would increase total net annual expenditures by $20,065,000, or 0.0136%, for enrollees with DMHC-regulated plans and CDI-regulated policies. The increase in total health insurance premiums paid by employers and enrollees for newly covered benefits is adjusted by a net decrease in cost sharing and enrollee expenses for covered and/or noncovered benefits.
Increases in premiums as a result of this bill would vary by market segment. CHBRP notes that such changes are related to the number of enrollees with health insurance that would be subject to this bill. Per member per month (PMPM) premium increases range from a high of 0.0912% in DMHC-regulated grandfathered small-group plans to a low of 0.0085% in CDI-regulated Individual other nongrandfathered policies. For enrollees associated with CalPERS in DMHC-regulated plans, the PMPM premium increase would be 0.0504%. For Medi-Cal beneficiaries enrolled in DMHC-regulated plans, there is no impact.
This bill's related changes in cost sharing for covered benefits (deductibles, copays, etc.) and out-of-pocket expenses for noncovered benefits would vary by market segment. CHBRP notes that such changes are related to the number of enrollees with health insurance that would be subject to this bill and expected to use the relevant STI screenings/tests, STI treatments, and other preventive services during the year after enactment. CHBRP also notes that decreases in expenses for non-covered benefits would be greater, on a per-person basis, for enrollees in grandfathered plans/policies. As cost sharing is not prohibited for STI treatments, and as increased screening would result in more treatment, there would be a net increase in cost sharing of 0.02%. Enrollee expenses for noncovered benefits would decrease by 1.84%.
Among the commercial/CalPERS enrollees who would use an STI screening test and for whom cost sharing would change, postmandate, the reduction in cost sharing would vary. Examples of the postmandate cost sharing reductions would include $5.00 for an STI panel (current procedural terminology (CPT) 80061) or $36.51 for an office visit (CPT 99214). Among the commercial/CalPERS enrollees who would use other preventive services and for whom cost sharing would change, postmandate, the reduction in cost sharing would vary. Examples of the postmandate cost sharing reductions would include $1.00 for a developmental test (CPT 96110) or as much as $72.78 for antepartum care (CPT 59426).
CHBRP estimates that the increase in administrative costs of DMHC-regulated plans and/or CDI-regulated policies will remain proportional to the increase in premiums. CHBRP assumes that if health care costs increase as a result of increased utilization or changes in unit costs, there is a corresponding proportional increase in administrative costs. CHBRP assumes that the administrative cost portion of premiums is unchanged. All health plans and insurers include a component for administration and profit in their premiums
According to the Author
Every Californian deserves access to preventive health care that is comprehensive, inclusive, and affordable. Current California law relating to preventive health care and screenings for STIs contains loopholes that need closing. The author concludes that this bill ensures that patients can access not only preventive care but also all of the services and office visits that are necessary for delivering that care without cost-sharing, including medication management and lab testing for preexposure prophylaxis (PrEP), a life-saving HIV prevention medication.
Arguments in Support
Equality California writes this bill will ensure that patients can access lifesaving preventive care – including all the services and office visits that are necessary for delivering that care – without cost sharing. This bill will also expand access to screening for STIs and help to address the state's growing STI epidemic among California youth, LGBTQ+ people, and communities of color. On March 30, 2023, a Texas federal judge issued a ruling in the case, Braidwood Management v. Becerra, striking down part of the ACA requiring no cost coverage of preventive services recommended or updated by the US Preventive Services Task Force. The federal government is currently appealing the decision. While California law will continue to require that all state-regulated health plans cover preventive services without cost sharing, there are loopholes that need closing. This bill will strengthen existing law in the face of these incessant judicial attacks on the ACA and ensure that health plans cover the full spectrum of preventive services without cost sharing, including office visits and other necessary health care services for delivering a preventive benefit. This bill will codify longstanding federal guidance that health plans must cover services that are 'integral' to preventive care – including anesthesia and polyp removal during a colonoscopy; placement, management, and removal of longacting reversible contraceptives; and lab testing for HIV PrEP – without cost sharing, while further requiring coverage of integral services consistent with current clinical best practices. Additionally, this bill will eliminate loopholes that allow cost sharing for recommended preventive care benefits in some instances. Every Californian deserves access to preventive health care that is comprehensive, inclusive, and affordable.
Arguments in Opposition
The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America's Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state's share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. All ACA-compliant plans provide a robust package of essential health benefits (EHBs) in the large group, small business, and individual markets (both on and off the Exchange). In the individual market, the ACA sought to preserve the balance between comprehensive coverage and affordability by requiring states to bear the cost for new mandates that exceed the EHB package. The Centers for Medicaid and Medicare Services recently affirmed that states are still responsible for defraying the cost of new mandates. The opposition states mandate bills will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options
FISCAL COMMENTS
According to the Assembly Appropriations Committee:
- No costs to CDI.
- DMHC estimates the total cost of this bill to be approximately $707,000 in fiscal year (FY) 2023-24 and $1.6 million in FY 2024-25 and annually thereafter.
- CHBRP estimates this bill will have no effect on costs to Medi-Cal.
- CHBRP estimates increases in CalPERS premiums of $3.1 million (0.05%); a substantial but unknown portion of these premiums is paid by the state (General Fund, special funds).
- CHBRP estimates this bill will increase total net annual expenditures by $20,065,000, or 0.01%, for DMHC-regulated plans and CDI-regulated policies. The increase in total health insurance premiums paid by employers and enrollees for newly covered benefits includes a reduction in enrollee expenditures of $7.7 million (1.84%) as a result of this bill.
VOTES
ASM HEALTH: 12-0-3
YES: Wood, Waldron, Aguiar-Curry, Arambula, Boerner, Wendy Carrillo, Maienschein, McCarty, Rodriguez, Santiago, Villapudua, Weber
ABS, ABST OR NV: Flora, Vince Fong, Joe Patterson
ASM APPROPRIATIONS: 11-2-3
YES: Holden, Bryan, Calderon, Wendy Carrillo, Mike Fong, Hart, Lowenthal, Papan, Pellerin, Weber, Ortega
NO: Megan Dahle, Dixon
ABS, ABST OR NV: Mathis, Robert Rivas, Sanchez
UPDATED
VERSION: May 1, 2023
CONSULTANT: Kristene Mapile / HEALTH / (916) 319-2097 FN: 0000831
Date of Hearing: May 17, 2023
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Chris Holden, Chair
ABPCA Bill Id:AB 1645
Author:(Zbur) – As Amended Ver:May 1, 2023
Policy Committee: | Health | Vote: | 12 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill prohibits a health plan contract or health insurance policy from requiring cost sharing for office visits of specified preventive care services and screenings and for items or services that are integral to the provision of those preventive care services.
This bill also prohibits a health plan contract or insurance policy from requiring cost sharing, utilization review, or other specified limits on a recommended sexually transmitted infection (STI) screening, and from imposing a cost-sharing requirement for any items and services integral to an STI screening. The bill requires a health plan or insurer to directly reimburse specified nonparticipating providers or facilities of STI screening a specified amount for the screening tests and related items and services and prohibits the nonparticipating provider from billing or collecting a cost-sharing amount for an STI screening from an enrollee or insured.
FISCAL EFFECT:
No costs to the California Department of Insurance (CDI).
The Department of Managed Health Care (DMHC) estimates the total cost of this bill to be approximately $707,000 in fiscal year (FY) 2023-24 and $1.6 million in FY 2024-25 and annually thereafter.
The California Health Benefits Review Program (CHBRP) estimates this bill will have no effect on costs to Medi-Cal.
CHBRP estimates increases in CalPERS premiums of $3.1 million (0.05%); a substantial but unknown portion of these premiums is paid by the state (General Fund, special funds).
CHBRP estimates this bill will increase total net annual expenditures by $20,065,000, or 0.01%, for DMHC-regulated plans and CDI-regulated policies. The increase in total health insurance premiums paid by employers and enrollees for newly covered benefits includes a reduction in enrollee expenditures of $7.7 million (1.84%) as a result of this bill.
COMMENTS:
- Purpose. This bill is sponsored by Insurance Commissioner Ricardo Lara, APLA Health, Equality California, Los Angeles LGBT Center, and the San Francisco AIDS Foundation. According to the author:
Every Californian deserves access to preventive health care that is comprehensive, inclusive, and affordable. Current California law relating to preventive health care and screenings for sexually transmitted infections (STIs) contains loopholes that need closing. AB 1645 ensures that patients can access not only preventive care but also all of the services and office visits that are necessary for delivering that care without cost-sharing, including medication management and lab testing for PrEP, a life-saving HIV prevention medication.
Currently, STI screening is covered without cost sharing if recommended by the U.S. Preventive Services Task Force (USPSTF), but these recommendations are narrower than guidelines of the U.S. Centers for Disease Control and Prevention (CDC). This proposal would apply the cost sharing exception based on the CDC’s more equitable STI screening guidelines.
- Public Health. According to CHBRP, the primary purpose of STI screening is to identify and treat new STI cases, which helps the infected person and decreases the spread of disease. Not all who test positive for STIs go on to get treatment. CHBRP has assumed the increase in STI screening due to this bill would increase treatment for HIV by 0.2%, treatment for hepatitis C by 0.9%, and treatment for all other STIs by 5%. CHBRP also estimates a reduction in self-pay (free STI clinics) of 7.27%. For HIV and hepatitis C, due to the lower prevalence of infection, treatment is not expected to increase to the same degree as for other STIs. Given the wider spread of HIV testing programs than programs for hepatitis C, the likelihood of finding a new positive due to increased testing under this bill is smaller than that for hepatitis C, which is not as widely tested.
- Long-term Effects. CHRBP estimates this bill will increase utilization of STI screening (117,200 tests), STI treatment (92,900 treatments), and other preventive services (116,000 services). Therefore, projected long-term public health impacts may include a reduction in future STI transmissions and associated long-term effects, such as a reduction in the prevalence of syphilis, a reduction in congenital syphilis, and a subsequent reduction in the number of overall adverse health outcomes for both mother and infant. CHBRP also notes the possibility of an overall reduction in downstream adverse effects due to increased use of other preventive services, such as potential increases in counseling related to smoking cessation leading to a reduction of lung cancer in the long-term, or potential increases in HPV vaccinations leading to a reduction in cervical cancer in the future.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 25, 2023
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 1645
Author:Zbur – As Amended Ver:March 20, 2023
SUBJECT: Health care coverage: cost sharing.
SUMMARY: Prohibits a group or individual nongrandfathered health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement for office visits of specified preventive care services and screenings and for items or services that are integral to their provision. Prohibits nongrandfathered and grandfathered health plan contracts and insurance policies from imposing a cost-sharing requirement, utilization review, or other specified limits on a recommended sexually transmitted infections (STI) screening, and from imposing a cost-sharing requirement for any items and services integral to a STI screening, as specified. Requires a health plan or insurer to directly reimburse specified nonparticipating providers or facilities of STI screening, its median contracted rate in the general geographic region for screening tests and integral items and services rendered, and prohibits the nonparticipating provider from billing or collecting a cost-sharing amount for a STI screening from an enrollee or insured. Specifically, this bill:
- Prohibits a health plan contract or insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing any cost-sharing requirement for office visits that are associated with the provision of an item or service required under 4) of existing law below, or for any items or services that are integral to the provision of an item or service, regardless of whether the office visit or integral item or service is billed, or tracked as individual encounter data, separately from an item or service, as specified.
- Defines the following:
- Integral item or service to mean an item, service, prescription drug, device, or product, or nonprescription drug, device, or product, that is a current, generally accepted standard of care or clinical practice for the provision of an item or service that is required by this bill;
- Current, generally accepted standard of care or clinical practice to mean standards of care and clinical practice that are generally accepted by health care providers practicing in relevant clinical specialties, such as family medicine, pediatrics, preventive medicine, infectious diseases, obstetrics and gynecology, and public health. Specifies that valid, evidence-based sources establishing current, generally accepted standards of care and clinical practice include peer-reviewed scientific studies and medical literature, the most recently updated clinical practice guidelines and recommendations of nonprofit health care provider professional associations, specialty societies and federal government agencies, including the American College of Obstetricians and Gynecologists and the federal Centers for Disease Control and Prevention (CDC), and product labeling approved by the United States Food and Drug Administration.
- Specifies that this bill does not prohibit a health plan or insurer from doing either of the following:
- Providing coverage for preventive items or services in addition to those required; or,
- Denying coverage for services that are not recommended by the United States Preventive Services Task Force (USPSTF), except as provided.
- Requires a health plan or insurer to provide coverage for modified or upgraded recommendations or guidelines no later than the first day of the plan year after the modification or upgrade was adopted or 90 days after the date on which the modification or upgrade was adopted, whichever is earlier in the calendar year.
- Requires a health plan contract or insurance policy to cover items and services pursuant to this bill, prophylaxis of HIV infection, STI screening, home test kits for sexually transmitted diseases (STDs), and colorectal cancer screening.
- Exempts grandfathered health plans from 1) to 5) above. Specifies that the cost-sharing requirements of this bill only apply to a health savings account (HSA)-eligible health plan or policy to the extent it does not fail to be treated as a high deductible health plan (HDHP) or policy, as specified.
- Prohibits a group or individual health plan contract or insurance policy issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement on a STI screening that is recommended by the CDC in the most recently updated version of its STI Treatment Guidelines, as subsequently modified by any published updates in the Morbidity and Mortality Weekly Report or similar method of official public communication. Prohibits a health plan contract or insurance policy from requiring any cost sharing for a STI screening, or for any items and services that are integral to a screening, that is performed by an essential community provider or participating provider, facility, or processing laboratory consistent with the CDC’s recommendation if a screening recommendation of the USPSTF conflicts with that of the CDC, or omits a CDC screening recommendation.
- Prohibits a health plan contract or insurance policy issued, amended, or renewed on or after January 1, 2024, from requiring or imposing any of the following for coverage of STI screening, or of any items and services that are integral to a screening, that is performed by an essential community provider (ECP) or participating provider, facility, or processing laboratory:
- Prior authorization or other utilization review requirements;
- Limits on frequency, method, treatment, or setting;
- Limits on confirmatory or post-treatment retesting of an asymptomatic patient;
- Limits that are based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening; and,
- Any other limits on the coverage or provision of STI screening as a preventive item or service under this bill, as a preventive basic health care service, or that constitutes a discriminatory benefit design or marketing practice as prohibited.
- Prohibits a health plan contract or insurance policy, issued, amended, or renewed on or after January 1, 2024, from imposing a cost-sharing requirement for STI screening, or for any items and services that are integral to a screening, as specified, regardless of any of the following:
- The location of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting;
- The screening test, testing method or algorithm, or method of sample collection or processing;
- The identity or qualifications of the individual who collected or processed a sample; and
- The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
- Requires a health plan or insurer to directly reimburse a nonparticipating provider or facility of STI screening its median contracted rate in the general geographic region for screening tests and integral items and services rendered, if the provider or facility was an ECP when the screening tests and integral items and services were rendered. Requires the provider to submit the samples to a participating processing laboratory if a nonparticipating ECP does not generate the results of screening. Prohibits a nonparticipating ECP from billing or collecting any cost-sharing amounts from an enrollee for a STI screening, or for integral items and services, as specified.
- Defines the following:
- ECP to mean a provider or facility that is eligible for listing, and is listed, on the California Health Benefit Exchange’s (Covered California or the Exchange) ECP List;
- Gender to mean sex, including gender identity and gender expression; and,
- Gender expression to mean gender-related appearance and behavior, whether or not stereotypically associated with assigned sex at birth.
- Exempts specialized health plan contracts and insurance policies, as defined. Prohibits a HDHP from imposing a deductible on STI screening, as specified, unless in conflict with HDHP federal requirements.
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans, and the California Department of Insurance (CDI) to regulate health insurance. [Health and Safety Code (HSC) § 1340, et seq., Insurance Code (INS) § 106, et seq., and HSC § 120125, et seq.]
- Establishes Covered California as an independent entity in state government not affiliated with any state agency or department, governed by a five-member board. Requires the Covered California Executive Board to establish and use a competitive process to select participating carriers and other contractors, and to make health insurance available to individuals and small businesses as authorized under the federal Patient Protection and Affordable Care Act (ACA). [Government Code § 100500 -100522]
- Establishes as California's essential health benefits (EHBs) benchmark under the ACA, the Kaiser Small Group Health Maintenance Organization, existing California health insurance mandates, and the 10 ACA mandated benefits, including prescription drug coverage. Non-grandfathered individual and small group health plan contracts and insurance policies are required to cover EHBs. [HSC §1367.005 and INS §10112.27]
- Requires health plans and insurers, at a minimum, to provide coverage for and prohibits any cost-sharing requirements for several services including, but not limited to evidence-based items or services that have in effect a rating of “A” or “B in the recommendations of the USPSTF and immunizations that have in effect a recommendation from the Advisory Committee on Immunization Practices (ACIP) of the CDC. [HSC §1367.002 and INS §10112.2]
- Requires health plans and insurers to provide coverage for home test kits for STDs, as defined, and the laboratory costs for processing those kits, that are deemed medically necessary or appropriate and ordered directly by a health care provider or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs. [HSC §1367.34 and INS §10123.208]
- Requires the criteria or guidelines used by health plans and insurers, or any entities with which plans or insurers contract for utilization review or utilization management functions, to determine whether to authorize, modify, or deny health care services to:
- Be developed with involvement from actively practicing health care providers;
- Be consistent with sound clinical principles and processes;
- Be evaluated, and updated if necessary, at least annually;
- If used as the basis of a decision to modify, delay, or deny services in a specified case under review, be disclosed to the provider and the enrollee or insured in that specified case; and,
- Be available to the public upon request. [HSC §1363.5 and INS §10123.135]
- Requires health plans and insurers and any contracted entity that performs utilization review or utilization management functions, retrospectively, or concurrently, based in whole or in part on medical necessity requests by providers related to health care services to enrollees or insureds, to comply with specified requirements. [HSC §1367.01 and INS §10123.135]
FISCAL EFFECT: Unknown. This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, every Californian deserves access to preventive health care that is comprehensive, inclusive, and affordable. Current California law relating to preventive health care and screenings for STIs contains loopholes that need closing. The author concludes that this bill ensures that patients can access not only preventive care but also all of the services and office visits that are necessary for delivering that care without cost-sharing, including medication management and lab testing for preexposure prophylaxis (PrEP), a life-saving HIV prevention medication.
- BACKGROUND. The California Health Benefits Review Program (CHBRP) writes that preventive services are services such as screening tests and counseling that aim to prevent illness and disease.
- Multiple sources make recommendations as to who should use which preventive services when, including:
- The USPSTF “A” and “B” recommendations: Includes counseling and screening for conditions such as cancer, cardiovascular disease, depression, diabetes, obesity, osteoporosis, and STIs and behaviors related to tobacco, alcohol, and drug use. The USPSTF offers recommendations for screenings of individuals that may be at higher risk for certain adverse health outcomes due to age, gender, and current health conditions;
- The Health Resources and Services Administration (HRSA)-supported health plan coverage recommendations for women’s preventive services: Includes preventive services that address mental health, sexual health (contraception and STI screening), cancer (breast, cervical), and overall wellness among women in general, and specific services for pregnant (diabetes, mental health, STI screening) and postpartum (breast feeding services and supplies, diabetes screening) women;
- The HRSA-supported comprehensive recommendations for infants, children, and adolescents which include: These recommendations include The Bright Futures Recommendations for Pediatric Preventive Health Care, and the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children. The Bright Futures recommendations provide recommendations for preventive care screenings and routine visits for newborns through age of 21 years. The recommendations of the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children focus on the implementation of a uniform screening panel in every newborn screening program, enabling screening for 36 core disorders and secondary disorders. Beyond newborn screening, the committee also provides recommendations regarding medical foods, specific health conditions, and health care reform: and,
- ACIP recommendations adopted by the CDC: The recommendations provided the recommended immunizations, immunization schedules, and catch-up immunization schedules for both children and adults. Recommendations also provide guidance in regards to vulnerable populations or emergency situations.
- Multiple sources make recommendations as to who should use which preventive services when, including:
Preventive services recommended in any of these four sources are required to be covered without cost-sharing initially required by the ACA and later codified in AB 306 (Pan), Chapter 486, Statutes of 2021. These requirements go into effect as soon as 12 months after a recommendation is issued. New recommendations or updated recommendations do appear periodically, as the sources consider changes in the health of the population and advances in science. This bill would add the CDC STI screening recommendations to this list of preventive services referenced in coverage mandates in California. This bill would not change the timing requirement for new recommendations but would require that coverage be compliant within 90 days of issue when an existing recommendation is modified or upgraded. CHBRP’s analysis states that this bill amends California’s preventive services mandate as follows:
- Under existing law:
- For commercial/CalPERS enrollees in nongrandfathered CDI-regulated policies and DMHC-regulated plans:
- Prohibits cost sharing for preventative items and services recommended by the USPSTF, ACIP, or HRSA– beginning in the plan or policy year that follows publication of the recommendation.
- Allows a deductible for enrollees in HSA qualified HDHP if not applying the deductible would disqualify the plan as a federally recognized HSA-HDHP.
- For commercial/CalPERS enrollees in nongrandfathered CDI-regulated policies and DMHC-regulated plans:
- This bill amends existing law to:
- Make compliance in no less than 90 days required for modified or upgraded preventive service recommendations (but not for new recommendations).
- Prohibit cost sharing for office visits and/or any item or service associated with provision of the referenced preventative items and services.
- Specify required compliance with existing California mandates that also address preventive services.
- This bill establishes a STI screening mandate to:
- For commercial/CalPERS enrollees in all CDI-regulated policies and DMHC-regulated plans grandfathered and nongrandfathered:
- Prohibits the application of cost sharing to coverage for STI screening – unless not applying the deductible for an enrollee in an HSA-HDHP would disqualify the plan as a federally recognized HSA-HDHP.
- Add the CDC STI screening recommendations to this list of preventive services referenced in coverage mandates in California and prohibit cost sharing for coverage for STI screenings or any related items or services, regardless of:
- For commercial/CalPERS enrollees in all CDI-regulated policies and DMHC-regulated plans grandfathered and nongrandfathered:
- Under existing law:
The location or method of sample collection or processing, including at locations that are both clinical and nonclinical in nature, regardless of whether a location constitutes a health care setting;
The screening test, testing method or algorithm, or method of sample collection or processing;
The identity or qualifications of the individual who collected or processed a sample; and,
The clinical circumstances of screening, including whether or not a screening was based on risk of infection, or there was an emergent or urgent need for immediate or prompt screening or the results of screening.
- When accessed through an ECP listed on the the Exchange’s ECP, or when accessed through a participating provider, prohibit, for coverage of STI screenings and for any related items:
Prior authorization or other utilization review requirements;
Limits on frequency, method, treatment, or setting;
Limits on confirmatory or post-treatment retesting of an asymptomatic patient;
Limits based on risk of infection, sexual behavior, sexual orientation, gender, or anatomical sites of screening;
Any other limits on the coverage or provision of STI screening as a preventive item or service under this section or other mandates related to STI screening, or that constitutes a discriminatory benefit design or marketing practice as prohibited by this this bill.
- Requires that nonparticipating ECPs be reimbursed at the median contracted rate in the general geographic region
- Barriers to Accessing STI Screening. CHBRP states that a number of barriers have been identified in accessing STI testing and related services, both in clinical and home settings, including clinic inaccessibility; lack of knowledge and/or awareness; concerns about patient privacy and confidentiality; patient stigma and/or embarrassment; patient discomfort; patient perceptions of risk and discrimination; lack of time needed to attend appointments; as well as lack of financial resources or insurance needed to pay for related health care costs. In addition, barriers to accessing at home-test kits also exist. Despite local health departments across the nation understanding the need to implement innovative STI testing strategies that also reduce stigma related to seeking testing and treatment, lack of funding mechanisms to support the provision of home-to-lab testing (i.e., inability to purchase sufficient test kits and required development of eligibility criteria), administrative roadblocks (i.e., difficulty in establishing order mechanisms for home-to-lab testing, insufficient staffing capacity, and low organizational buy-in), and limited validation of STI home-to-lab test kits by public health laboratories were cited as leading barriers to implementation. According to CHBRP, a number of disparities in preventive services utilization and prevalence of STIs exist in the United States; and it is possible that disparities in STIs by gender identity and sexual orientation may decrease as a result of this bill.
- Covered California’s Consolidated ECP List. This bill requires coverage of nonparticipating ECP providers. Covered California is dedicated to inclusion of ECPs who serve the low-income and medically underserved communities in provider networks offered by its Qualified Health Plans. The Federal 340B list of ECPs is a critical category of ECPs but does not constitute the sole source of such entities. There are some provider organizations that serve the low-income and medically underserved population that are not 340Bs, as specified below. Covered California's Consolidated ECP list is an attempt to create a single, non-duplicated list of ECPs that potentially could serve Covered California enrollees. Current categories of ECPs are listed below and are included in the Consolidated ECP List:
- 340B entities (clinics, hospitals and other entities);
- California Disproportionate Share Hospitals, defined by the California Department of Health Care Services;
- Federally Qualified Health Centers;
- Federally designated 638 Tribal Health Programs and Title V Urban Indian Health Organizations;
- Providers licensed as "community clinic" or "free clinic" under California Health and Safety Code 1204(a), or is a community or free clinic exempt from licensure under 1206;
- Providers who qualified for HI-TECH Medi-Cal Electronic Health Record Incentive Program dollars. These are eligible providers who completed the application process for this federal program, administered by the California Department of Health Care Services, to distribute financial resources to encourage providers to establish electronic medical records.
- CHBRP analysis. AB 1996 (Thomson), Chapter 795, Statutes of 2002, requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost sharing, premiums, and other health insurance topics. CHBRP states the following in its analysis of this bill:
Enrollees covered. For STI screening, at baseline, 0% of the 14 million commercial/CalPERS enrollees have insurance that is fully compliant with the requirements of this bill with regard to cost sharing and only 18% have insurance that is fully compliant with the requirements of this bill with regard to being able to see a nonparticipating provider without prior authorization. Postmandate, all commercial/ CalPERS enrollees would have benefit coverage compliant with the STI screening mandate of this bill.
- Impact on expenditures. According to CHBRP, this bill would increase total net annual expenditures by $20,065,000, or 0.0136%, for enrollees with DMHC-regulated plans and CDI-regulated policies. The increase in total health insurance premiums paid by employers and enrollees for newly covered benefits is adjusted by a net decrease in cost sharing and enrollee expenses for covered and/or noncovered benefits.
Increases in premiums as a result of this bill would vary by market segment. CHBRP notes that such changes are related to the number of enrollees with health insurance that would be subject to this bill. Per member per month (PMPM) premium increases range from a high of 0.0912% in DMHC-regulated grandfathered small-group plans to a low of 0.0085% in CDI-regulated Individual other nongrandfathered policies. For enrollees associated with CalPERS in DMHC-regulated plans, the PMPM premium increase would be 0.0504%. For Medi-Cal beneficiaries enrolled in DMHC-regulated plans, there is no impact.
This bill’s related changes in cost sharing for covered benefits (deductibles, copays, etc.) and out-of-pocket expenses for noncovered benefits would vary by market segment. CHBRP notes that such changes are related to the number of enrollees with health insurance that would be subject to this bill and expected to use the relevant STI screenings/tests, STI treatments, and other preventive services during the year after enactment. CHBRP also notes that decreases in expenses for non-covered benefits would be greater, on a per-person basis, for enrollees in grandfathered plans/policies. As cost sharing is not prohibited for STI treatments, and as increased screening would result in more treatment, there would be a net increase in cost sharing of 0.02%. Enrollee expenses for noncovered benefits would decrease by 1.84%.
Among the commercial/CalPERS enrollees who would use an STI screening test and for whom cost sharing would change, postmandate, the reduction in cost sharing would vary. Examples of the postmandate cost sharing reductions would include $5.00 for an STI panel (CPT 80061) or $36.51 for an office visit (CPT 99214). Among the commercial/CalPERS enrollees who would use other preventive services and for whom cost sharing would change, postmandate, the reduction in cost sharing would vary. Examples of the postmandate cost sharing reductions would include $1.00 for a developmental test (CPT 96110) or as much as $72.78 for antepartum care (CPT 59426).
CHBRP estimates that the increase in administrative costs of DMHC-regulated plans and/or CDI-regulated policies will remain proportional to the increase in premiums. CHBRP assumes that if health care costs increase as a result of increased utilization or changes in unit costs, there is a corresponding proportional increase in administrative costs. CHBRP assumes that the administrative cost portion of premiums is unchanged. All health plans and insurers include a component for administration and profit in their premiums
- EHBs. This bill does not to exceed the definition of EHBs in California.
- Medical effectiveness. Based on the recommendations from the four entities referenced by the CDC mandates, as well as recommendations from the CDC, CHBRP considers all of the recommended preventive services and STI screenings to have clear and convincing evidence of medical effectiveness. Although CHBRP found insufficient evidence that the prohibition of cost sharing would substantially impact utilization, this conclusion is based on a generalized summary across a variety of preventive services.
- Utilization. CHBRP estimates 25% of all STI testing and treatment is done on a self-pay basis among insured enrollees at baseline and postmandate due to privacy preferences. Thus, 75% are purchased with insurance, and only this subset will experience changes due to removal of cost-sharing and prior authorization. However, this is an overall estimate and varies across the following categories. Utilization for STI screening can be accessed in three ways: 1) Home test kits; 2) participating providers; and, nonparticipating providers (limited to ECPs in this bill).
- Public health. The primary purpose of STI screening is to identify and treat new STI cases, which both helps the infected person and decreases the spread of the disease. Evidence suggests that not all who test positive for STIs go on to get treatment. CHBRP has assumed the increase in STI screening due to this bill would increase treatment for HIV by 0.2%, treatment for hepatitis C by 0.9%, and treatment for all other STIs by 5%. CHBRP also estimates a reduction in self-pay (free STI clinics) of 7.27%. For HIV and hepatitis C, due to the lower prevalence of infection, treatment is not expected to increase to the same degree as for other STIs. Given the wider spread of HIV testing programs, the likelihood of finding a new positive due to increased testing due to this bill is smaller than that for hepatitis C, which is not as widely tested.
- Long-term impacts. This bill would increase utilization of both STI screening (117,200 tests), STI treatment (92,900 treatments), and other preventive services (116,000 services). Therefore, projected long-term public health impacts may include a reduction in future STI transmissions (such as a reduction in the prevalence of syphilis leading to a reduction in congenital syphilis leading to a subsequent reduction in the number of overall adverse health outcomes among both mother and infant in the long-term), and an overall reduction in downstream effects such as impact on premature death and economic loss. Long-term impacts from increased other preventive services is expected as well such as potential increases in counseling related to smoking cessation leading to a reduction of lung cancer in the long-term or potential increases in HPV vaccinations leading to a reduction in cervical cancer in the future.
- SUPPORT. Equality California writes this bill will ensure that patients can access lifesaving preventive care – including all the services and office visits that are necessary for delivering that care – without cost sharing. This bill will also expand access to screening for STIs and help to address the state’s growing STI epidemic among California youth, LGBTQ+ people, and communities of color. On March 30, 2023, a Texas federal judge issued a ruling in the case, Braidwood Management v. Becerra, striking down part of the ACA requiring no cost coverage of preventive services recommended or updated by the USPSTF. The federal government is currently appealing the decision. While California law will continue to require that all state-regulated health plans cover preventive services without cost sharing, there are loopholes that need closing. This bill will strengthen existing law in the face of these incessant judicial attacks on the ACA and ensure that health plans cover the full spectrum of preventive services without cost sharing, including office visits and other necessary health care services for delivering a preventive benefit. This bill will codify longstanding federal guidance that health plans must cover services that are ‘integral’ to preventive care – including anesthesia and polyp removal during a colonoscopy; placement, management, and removal of longacting reversible contraceptives; and lab testing for HIV PrEP – without cost sharing, while further requiring coverage of integral services consistent with current clinical best practices. Additionally, this bill will eliminate loopholes that allow cost sharing for recommended preventive care benefits in some instances. Every Californian deserves access to preventive health care that is comprehensive, inclusive, and affordable.
- OPPOSITION. The California Association of Health Plans, the Association of California Life and Health Insurance Companies, and America’s Health Insurance Plans write that state mandates increase costs of coverage, especially for families who buy coverage without subsidies, small business owners who cannot or do not wish to self-insure, and California taxpayers who foot the bill for the state’s share of those mandates. Health plans compete for business based on innovative benefit designs that increase access to care, improve quality, and contain costs. All ACA-compliant plans provide a robust package of EHBs in the large group, small business, and individual markets (both on and off the Exchange). In the individual market, the ACA sought to preserve the balance between comprehensive coverage and affordability by requiring states to bear the cost for new mandates that exceed the EHB package. The Centers for Medicaid and Medicare Services recently affirmed that states are still responsible for defraying the cost of new mandates. The opposition states mandate bills will increase costs and limit flexibility for employers. Faced with higher costs, employers must make difficult decisions about whether to absorb premium increases or seek alternative coverage options.
- RELATED LEGISLATION.
- SB 339 (Wiener) authorizes a pharmacist to furnish up to a 90-day course of PreEP, or preexposure prophylaxis (PEP) beyond a 90-day course, if specified conditions are met. Requires a health plan and health insurer to cover PrEP and PEP furnished by a pharmacist, including costs for the pharmacist’s services and related testing ordered by the pharmacist, and reimburse pharmacist services at 100% of the fee schedule for physician services. Includes PrEP furnished by a pharmacist as pharmacist services on the Medi-Cal schedule of benefits. SB 339 is pending in Senate Health Committee.
- AB 632 (Gipson) prohibits a health plan or a health insurance policy issued, amended, renewed, or delivered on or after January 1, 2024, from applying a deductible, copayment, or coinsurance to coverage for prostate cancer screening services for an enrollee or insured who is 55 years of age or older or who is 40 years of age or older and is high risk, as determined by the attending or treating health care provider. Defines high risk to include a person with a prostate who is Black, has a family history of prostate cancer, has a genetic predisposition to prostate cancer, or is a veteran. Specifies that for HDHP, this bill is subject to federal guidance on the preventive care safe harbor. AB 632 is pending in Assembly Appropriations Committee.
- PREVIOUS LEGISLATION.
- SB 306 (Pan), Chapter 486, Statutes of 2021, permits pharmacists to dispense a drug, without the name of an individual for whom the drug is intended, when prescribed for the sexual partner of someone who has been diagnosed with a STD; prohibits health care providers who prescribe, dispense, or furnish such a drug from being subject to, civil, criminal, or administrative penalties, as specified; requires a syphilis blood test, during the third trimester of pregnancy and at delivery, as specified; requires public and commercial health coverage of home STD test kits; and adds rapid STD tests to existing law which permits HIV counselors to perform rapid HIV and hepatitis C tests.
- AB 342 (Gipson), Chapter 436, Statutes of 2021, requires a health plan contract or a health insurance policy, except as specified, that is issued, amended, or renewed on or after January 1, 2022, to provide coverage for a colorectal cancer screening test, and would require the required colonoscopy for a positive result on a test or procedure to be provided without cost sharing, unless the underlying test or procedure was a colonoscopy.
- SB 159 (Wiener), Chapter 532, Statutes of 2019, authorizes a pharmacist to initiate and furnish HIV PrEP and PEP, as specified.
- AB 72 (Bonta), Chapter 492, Statutes of 2016, establishes a payment rate, which is the greater of the average of a health plan or health insurer’s contracted rate, as specified, or 125% of the amount Medicare reimburses for the same or similar services; and an independent dispute resolution process for claims and claim disputes related to covered services provided at a contracted health facility by a non-contracting individual health care professional for health plan contracts and health policies issued, amended, or renewed on or after July 1, 2017. Limits enrollee and insured cost sharing for these covered services to no more than the cost sharing required had the services been provided by a contracting health professional.
- AMENDMENTS. The Committee recommends the “median contracted” rate for nonparticipating providers to be consistent with the nonparticipating provider rates from AB 72 noted in 6)d) above to be the greater of the average of a health plan or insurer’s contracted rate, or 125% of the amount Medicare reimburses for the same or similar services.
- POLICY COMMENTS. As this bill moves forward, the author may wish to consider a delayed implementation for health plan coverage to address changes to Covered California’s standard benefit design, if any.
REGISTERED SUPPORT / OPPOSITION:
Support
APLA Health (sponsor)
Equality California (sponsor)
California Department of Insurance (sponsor)
Los Angeles LGBT Center (sponsor)
San Francisco AIDS Foundation (sponsor)
AIDS Healthcare Foundation
Asian Liver Center At Stanford University
Bienestar Human Services
California Department of Insurance
California Hepatitis Alliance (CALHEP)
California LGBTQ Health and Human Services Network
California Life Sciences
Community Clinic Association of Los Angeles County (CCALAC)
End Hep C SF
End the Epidemics: Californians Mobilizing to End HIV, Viral Hepatitis, STIs, and Overdose
Equality California
Essential Access Health
Health Access California
Justice in Aging
Lyon-Martin Health Services
National Health Law Program
Planned Parenthood Affiliates of California
Radiant Health Centers
SF Hep B Free - Bay Area
Somos Familia Valle
The Source LGBT+ Center
Western Center on Law & Poverty, INC.
Opposition
America's Health Insurance Plans (AHIP)
Association of California Life & Health Insurance Companies
California Association of Health Plans
California Chamber of Commerce
Analysis Prepared by: Kristene Mapile / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):